CA2648360A1 - Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties - Google Patents
Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties Download PDFInfo
- Publication number
- CA2648360A1 CA2648360A1 CA002648360A CA2648360A CA2648360A1 CA 2648360 A1 CA2648360 A1 CA 2648360A1 CA 002648360 A CA002648360 A CA 002648360A CA 2648360 A CA2648360 A CA 2648360A CA 2648360 A1 CA2648360 A1 CA 2648360A1
- Authority
- CA
- Canada
- Prior art keywords
- less
- oil
- active agent
- composition
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 241
- 230000000843 anti-fungal effect Effects 0.000 title abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 20
- 230000000656 anti-yeast Effects 0.000 title abstract description 20
- 230000000840 anti-viral effect Effects 0.000 title abstract description 18
- 239000013543 active substance Substances 0.000 claims abstract description 220
- 238000000034 method Methods 0.000 claims abstract description 73
- 239000003921 oil Substances 0.000 claims description 84
- 235000019198 oils Nutrition 0.000 claims description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 78
- 239000002245 particle Substances 0.000 claims description 56
- 230000000845 anti-microbial effect Effects 0.000 claims description 52
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 46
- 239000000839 emulsion Substances 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 38
- -1 aromatic alcohols Chemical class 0.000 claims description 31
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 30
- 239000003381 stabilizer Substances 0.000 claims description 30
- 239000004094 surface-active agent Substances 0.000 claims description 25
- 229930182833 estradiol Natural products 0.000 claims description 22
- 229960005309 estradiol Drugs 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 229960003604 testosterone Drugs 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 18
- 241000228245 Aspergillus niger Species 0.000 claims description 14
- 241000222122 Candida albicans Species 0.000 claims description 14
- 239000004599 antimicrobial Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 11
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 11
- 235000012424 soybean oil Nutrition 0.000 claims description 11
- 239000003549 soybean oil Substances 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 150000001298 alcohols Chemical class 0.000 claims description 10
- 239000002202 Polyethylene glycol Chemical class 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 7
- 241000228197 Aspergillus flavus Species 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 229960004150 aciclovir Drugs 0.000 claims description 5
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004343 alendronic acid Drugs 0.000 claims description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 150000002194 fatty esters Chemical class 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 235000012343 cottonseed oil Nutrition 0.000 claims description 4
- 239000002385 cottonseed oil Substances 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- 239000010699 lard oil Substances 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 239000010466 nut oil Substances 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000000312 peanut oil Substances 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- 235000011803 sesame oil Nutrition 0.000 claims description 4
- 239000008159 sesame oil Substances 0.000 claims description 4
- 229940093609 tricaprylin Drugs 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 3
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 3
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 3
- 244000018633 Prunus armeniaca Species 0.000 claims description 3
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 3
- 244000044822 Simmondsia californica Species 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021324 borage oil Nutrition 0.000 claims description 3
- 239000000828 canola oil Substances 0.000 claims description 3
- 235000019519 canola oil Nutrition 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 150000002314 glycerols Chemical class 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 229940100242 glycol stearate Drugs 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 235000021388 linseed oil Nutrition 0.000 claims description 3
- 239000000944 linseed oil Substances 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229940068965 polysorbates Drugs 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 235000020238 sunflower seed Nutrition 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 239000010497 wheat germ oil Substances 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960003086 naltrexone Drugs 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 230000000249 desinfective effect Effects 0.000 claims 1
- 229940113088 dimethylacetamide Drugs 0.000 claims 1
- LBOVMDOAMWYGHK-UHFFFAOYSA-N ethanol;methylsulfinylmethane Chemical compound CCO.CS(C)=O LBOVMDOAMWYGHK-UHFFFAOYSA-N 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 abstract description 11
- 239000000969 carrier Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
- 235000019441 ethanol Nutrition 0.000 description 41
- 230000009467 reduction Effects 0.000 description 40
- 238000009472 formulation Methods 0.000 description 32
- 239000002552 dosage form Substances 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 24
- 239000002105 nanoparticle Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 15
- 229920000053 polysorbate 80 Polymers 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 241000233866 Fungi Species 0.000 description 14
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 14
- 229940068968 polysorbate 80 Drugs 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 239000000284 extract Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000265 homogenisation Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 238000000227 grinding Methods 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229940100611 topical cream Drugs 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 238000001238 wet grinding Methods 0.000 description 7
- 206010003487 Aspergilloma Diseases 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- 229920001993 poloxamer 188 Polymers 0.000 description 6
- 229940100617 topical lotion Drugs 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000009775 high-speed stirring Methods 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 201000009085 invasive aspergillosis Diseases 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 108060001064 Calcitonin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 4
- 229960002297 fenofibrate Drugs 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000010951 particle size reduction Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 3
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 101710142969 Somatoliberin Proteins 0.000 description 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000002864 food coloring agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- 229960004134 propofol Drugs 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 101100379079 Emericella variicolor andA gene Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000022569 Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 101100513046 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) eth-1 gene Proteins 0.000 description 1
- 101100016034 Nicotiana tabacum APIC gene Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940062331 androgel Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229960003093 antiseptics and disinfectants Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940002010 banana extract Drugs 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940064258 estrace Drugs 0.000 description 1
- 229940074117 estraderm Drugs 0.000 description 1
- 229940112314 estradiol topical lotion Drugs 0.000 description 1
- 229940098618 estring Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940125696 genitourinary agent Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940083404 gynodiol Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002372 hematologic agent Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000036732 invasive candidiasis Diseases 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940013712 pineapple extract Drugs 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229940034343 striant Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 239000008243 triphasic system Substances 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 239000002996 urinary tract agent Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940053743 vivelle Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/02—Acyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Agronomy & Crop Science (AREA)
- Epidemiology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties. The compositions are useful as drug delivery carriers for one or more active agents or, in the absence of an active agent, in methods where such compositions are desirable.
Description
NANOSTRUCTURED COMPOSITIONS HAVING ANTIBACTERIAL, ANTI-FUNGAL, ANTI-YEAST, AND/OR ANTI-VIRAL PROPERTIES
FIELD OF THE INVENTION
The invention is directed to nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties. The compositions are useful as drug delivery carriers for one or more active agents or, in the absence of an active agent, in methods where such compositions are desirable.
BACKGROUND
A. Background Regarding the Use of Antibacterial Agents in Drug Dosage Forms and Consumer Use Products Microbial preservatives are added to nonsterile dosage forms to protect them from microbiological growth or from microorganisms that are introduced inadvertently during or subsequent to the manufacturing process. In the case of sterile articles used in multi-dose containers, antimicrobial preservatives are added to inhibit the growth of microorganisms that may be introduced by repeatedly withdrawing individual doses.
All useful antimicrobial agents are toxic substances. See USP 26, General Chapters, Section 51, "Antimicrobial Effectiveness Testing." For maximum protection of patients, the concentration of the preservative shown to be effective in the final prepared packaged product should be below a level that may be toxic to humans.
U.S. Food and Drug Administration guidelines require that antimicrobial effectiveness, whether inherent in the product (i. e. , for an antibiotic agent) or whether produced because of the addition of an antimicrobial agent, must be demonstrated for all injections packaged in multiple-dose containers or for other products containing antimicrobial preservatives. Antimicrobial effectiveness must be demonstrated for multiple-dose topical and oral dosage forms, and for other dosage forms such as ophthalmic, otic, nasal, irrigation, and dialysis fluids. See USP 26, General Chapters, Section 51, "Antimicrobial Effectiveness Testing."
The addition of an antimicrobial agent to a therapeutic dosage form can be undesirable, as such compounds can be toxic and they can have undesirable interactions with the primary active agent to be delivered. In addition, the use of microbiocides can promote the generation of drug resistant bacteria, drug resistant yeast, drug resistant fungi, etc. This has been observed with the wide spread use of antibacterial lotions, soaps, cleaning products, etc.
Antibiotic resistance among bacteria has increased in recent years, and concerns have been raised that cross resistance might develop in bacteria or other microorganisms due to exposure to antibiotics or biocides. Rutala, W. A., "APIC Guideline for Selection and Use of Disinfectants," American J., 24:313-342 (1996); Russell et al., "Do Antiseptics and Disinfectants Select for Antibiotic Resistance?" J. of Medicinal Microbiology, 48:613-615 (1999). More effective disinfectants can be extremely irritant and toxic, resulting in health complications such as contact dermatitis and mucous membrane irritation among personnel.
Hansen, K.S., "Occupational Dermatoses in Hospital Cleaning Women," Contact Dermatitis, 9:343-351 (1983); Beauchamp et al., "A Critical Review of the Toxicology of Glutaraldehyde, Critical Reviews in Toxicology, 22:143-174 (1992). Thus, there is a continuing need for effective and safe biocidal agents for topical and surface disinfection and microorganisms change and resistant strains develop.
B. Background Regarding Fungal, Bacterial, Yeast, and Viral Opportunistic Organisms The USP specifies testing for effectiveness in killing E. colf, P. aeruginosa, and S.
aureus, plus acting to control and limit the growth of C. albicans, and A.
niger, to determine the antimicrobial effectiveness of a dosage form. See USP 26 Section 51, General Chapters, "Antimicrobial Effectiveness Testing." These particular microorganisms are representative of the most problematic and troublesome bacteria, fungi, and yeast.
Aspergillus niger is a fungus and one of the most common species of the genus Aspergillus. It causes black mold on certain types of fruit and vegetables, and is a common contaminant of food.
C. albicans is the major fungal pathogen of humans. Infections can be localized, such as vaginal infections and oral infections, which cause a considerable degree of discomfort. In some patient groups, whose defense system is severely compromised (prematurely born infants, leukemics and burn patients), the yeast can turn into a deadly pathogen causing systemic infections - up to 50% of the patients infected die as a result. The incidence of such infections is increasing rapidly, especially in hospitalized patients. In New Zealand, such infections are now ten times more frequent than they were 15 years ago.
Moreover, the reservoir of anti-Candida. drugs is very limited, and these agents'can have severe side effects.
E. coli is an ubiquitous bacteria, with a large number of known strains. The particularly nasty E. coli strain E. coli 0157:H7 is a member of the EHEC -enterohemorrhagic E. coll group. Enterohemorrhagic means an intestinally-related organism which causes hemorrhaging - and therefore, loss of blood. E. coli 0157:H7 produces a toxin, called Shiga-like toxin (SLT) or Vero toxin. The toxin is a protein which causes severe damage to intestinal epithelial cells. This condition is particularly dangerous to small children, and may be lethal, as children are too small to tolerate significant blood and fluid loss. In some cases another syndrome is involved which is called hemolytic uremic syndrome (HUS), which is characterized by kidney failure and loss of red blood cells.
Approximately 5% to 10% of children progress to this stage of disease. In severe cases, the disease can cause permanent kidney damage. The presence of this bacterium can also be very dangerous to the elderly or infirm. There can be a combination of HUS and other factors which involve the blood system, which can be lethal to the elderly in 50% of the cases. There is evidence that E. coli 0157:H7 is becoming more prevalent.
Pseudo zonas aeruginosa is a Gram-negative bacterium that is noted for its environmental versatility, ability to cause disease in particularly susceptible individuals, and its resistance to antibiotics. The most serious complication of cystic fibrosis is respiratory tract infection by the ubiquitous bacterium Pseudomonas aeruginosa. Cancer and burn patients also commonly suffer serious infections by this organism, as do certain other individuals with immune systems deficiencies. Unlike many environmental bacteria, P.
aeruginosa has a remarkable capacity to cause disease in susceptible hosts. It has the ability to adapt to and thrive in many ecological niches, from water and soil to plant and animal tissues. The bacterium is capable of utilizing a wide range of organic compounds as food sources, thus giving it an exceptional ability to colonize ecological niches where nutrients are limited. P. aeruginosa can produce a number of toxic proteins which not only cause extensive tissue damage, but also interfere with the human immune system's defense mechanisms. These proteins range from potent toxins that enter and kill host cells at or near the site of colonization to degradative enzymes that permanently disrupt the cell membranes and connective tissues in various organs.
Staphylococcus aureus is a leading cause of soft tissue infections, as well as toxic shock syndrome (TSS) and scalded skin syndrome. The pathogenic effects of Staph are mainly associated with the toxins it produces. Most of these toxins are produced in the stationary phase of the bacterial growth curve. In fact, it is not uncommon for an infected site to contain no viable Staph cells. The S. aureus enterotoxin causes quick onset food poisoning which can lead to cramps and severe vomiting. Infection can be traced to contaminated meats which have not been fully cooked. These microbes also secrete leukocidin, a toxin which destroys white blood cells and leads to the formation of pus and acne.
Particularly, S.
aureus has been found to be the causative agent in such ailments as pneumonia, meningitis, boils, arthritis, and osteomyelitis (chronic bone infection). Most S. aureus are penicillin resistant, but vancomycin and nafcillin are known to be effective against most strains.
The molds such as Aspergillus fumigatus are filamentous fizngi. They are especially prevalent growing on the nonliving organic materials in the soil. They disperse their non-sexual spores called conidia in the air. Most Aspergilli are harmless to humans and A.
fumigatus in particular is harmless to humans whose immune system has not been compromised by disease, drug therapy or genetic conditions. Exposure to A.
fumigatus can cause an allergic response in sensitive individuals. More importantly, A.
fumigatus is an opportunistic pathogen of bone marrow transplant patients, AIDS patients, and other immune compromised individuals.
Aspergillusfumigatus is the most common mold causing infection worldwide. The first infection described in man, an aspergilloma, was reported in Edinburgh in 1842 and many cases of invasive disease in non-immunocompromised patients have been reported.
These cases and more recent epidemiological data emphasize that A. fumigatus is a primary, albeit rare, pathogen of man. Allergic disease due to Aspergillus was first described in London in 1952 and the first invasive (and fatal) infection in an immunocompromised patient was described in 1953 in the British Medical Journal in a patient from Gloucester.
The frequency of invasive disease has risen approximately 14-fold over the 12 years to 1992, as judged after death in unselected autopsies. Invasive aspergillosis has overtaken candidiasis as the most frequent fiun.gal pathogen detected post mortem in tertiary care hospitals in Europe. Thus 4% of all patients dying had invasive aspergillosis, compared with about 2% with invasive candidiasis. Patients at risk based on the disease frequency include those with chronic granulomatous disease (25-40%), lung transplant recipients (17-26%), allogeneic bone marrow transplant patients (4-30%), neutropenic patients with leukemia (5-25%), heart transplant recipients (2-13%), pancreas transplant recipients (1-4%), renal transplant patients in Europe and the USA (- 1%) and in India (-10%), and patients with AIDS, multiple myeloma and severe combined immunodeficiency (-4%). Over 500,000 transplants are performed annually in the world. Acute leukemia affects about 3/100,000 of the population and on average each patient receives 3 cycles of chemotherapy, with each cycle defining a major risk period. Similar incidence is observed for high grade lymphoma patients who are also at high risk of invasive aspergillosis. In the industrialized nations alone these treatment protocols generate about 250,000 periods of major risk per year. AIDS cases are predicted to exceed 40 million by the end of the year 2000 which would result in about 1.4 million cases of invasive aspergillosis, although in developing countries most patients will not live long enough to get this disease.
The crude mortality from invasive aspergillosis is around 85% and falls to around 50% if treated. The new drugs in trial (voriconazole, etc.) may reduce the mortality slightly (-r10%), but patients in trials tend to do better than those treated in clinical practice. In addition to invasive disease, Aspergillus causes a number of other diseases in man. These include aspergilloma ("colonization" of existing pulmonary cavities), sinusitis in normal people, allergic bronchopulmonary and sinus infections, keratitis (which usually leads to blindness in that eye and is common in the developing world) and postoperative infections in immunocompetent patients. Aspergilloma numbers are set to rise dramatically due to the increasing incidence of tuberculosis and such aspergilloma cases are notoriously difficult to treat. Cavities of 2 cm or larger after tuberculosis subsequently develop aspergillomas in 15-20% of patients (in the UK). The 5 year survival of patients with aspergillomas is about 40%. Allergic bronchopulmonary aspergillosis occurs in patients with cystic fibrosis and asthmatics (an increasing number) causing pulmonary fibrosis and death usually within 10 years of diagnosis.
Aspergillus flavus is the etiologic agent in a wide range of infections including mycotoxicoses owing to aflotoxins, hypersensitivity pneumonitis, otitis, sinusitis, and invasive disease. Some reports suggest the disease process may be potentiated by aflotoxins, particularly in the immunocompromised/neutropenic host. The organism is extremely angioinvasive with resultant necrosis and infarction.
C. Prior Art Drug Delivery Techniques Ease of active pharmaceutical agent delivery is a key issue facing pharmaceutical companies that develop and commercialize therapeutic products. An active agent that is readily soluble in water, for example, is not difficult to formulate into a suitable dosage form.
FIELD OF THE INVENTION
The invention is directed to nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties. The compositions are useful as drug delivery carriers for one or more active agents or, in the absence of an active agent, in methods where such compositions are desirable.
BACKGROUND
A. Background Regarding the Use of Antibacterial Agents in Drug Dosage Forms and Consumer Use Products Microbial preservatives are added to nonsterile dosage forms to protect them from microbiological growth or from microorganisms that are introduced inadvertently during or subsequent to the manufacturing process. In the case of sterile articles used in multi-dose containers, antimicrobial preservatives are added to inhibit the growth of microorganisms that may be introduced by repeatedly withdrawing individual doses.
All useful antimicrobial agents are toxic substances. See USP 26, General Chapters, Section 51, "Antimicrobial Effectiveness Testing." For maximum protection of patients, the concentration of the preservative shown to be effective in the final prepared packaged product should be below a level that may be toxic to humans.
U.S. Food and Drug Administration guidelines require that antimicrobial effectiveness, whether inherent in the product (i. e. , for an antibiotic agent) or whether produced because of the addition of an antimicrobial agent, must be demonstrated for all injections packaged in multiple-dose containers or for other products containing antimicrobial preservatives. Antimicrobial effectiveness must be demonstrated for multiple-dose topical and oral dosage forms, and for other dosage forms such as ophthalmic, otic, nasal, irrigation, and dialysis fluids. See USP 26, General Chapters, Section 51, "Antimicrobial Effectiveness Testing."
The addition of an antimicrobial agent to a therapeutic dosage form can be undesirable, as such compounds can be toxic and they can have undesirable interactions with the primary active agent to be delivered. In addition, the use of microbiocides can promote the generation of drug resistant bacteria, drug resistant yeast, drug resistant fungi, etc. This has been observed with the wide spread use of antibacterial lotions, soaps, cleaning products, etc.
Antibiotic resistance among bacteria has increased in recent years, and concerns have been raised that cross resistance might develop in bacteria or other microorganisms due to exposure to antibiotics or biocides. Rutala, W. A., "APIC Guideline for Selection and Use of Disinfectants," American J., 24:313-342 (1996); Russell et al., "Do Antiseptics and Disinfectants Select for Antibiotic Resistance?" J. of Medicinal Microbiology, 48:613-615 (1999). More effective disinfectants can be extremely irritant and toxic, resulting in health complications such as contact dermatitis and mucous membrane irritation among personnel.
Hansen, K.S., "Occupational Dermatoses in Hospital Cleaning Women," Contact Dermatitis, 9:343-351 (1983); Beauchamp et al., "A Critical Review of the Toxicology of Glutaraldehyde, Critical Reviews in Toxicology, 22:143-174 (1992). Thus, there is a continuing need for effective and safe biocidal agents for topical and surface disinfection and microorganisms change and resistant strains develop.
B. Background Regarding Fungal, Bacterial, Yeast, and Viral Opportunistic Organisms The USP specifies testing for effectiveness in killing E. colf, P. aeruginosa, and S.
aureus, plus acting to control and limit the growth of C. albicans, and A.
niger, to determine the antimicrobial effectiveness of a dosage form. See USP 26 Section 51, General Chapters, "Antimicrobial Effectiveness Testing." These particular microorganisms are representative of the most problematic and troublesome bacteria, fungi, and yeast.
Aspergillus niger is a fungus and one of the most common species of the genus Aspergillus. It causes black mold on certain types of fruit and vegetables, and is a common contaminant of food.
C. albicans is the major fungal pathogen of humans. Infections can be localized, such as vaginal infections and oral infections, which cause a considerable degree of discomfort. In some patient groups, whose defense system is severely compromised (prematurely born infants, leukemics and burn patients), the yeast can turn into a deadly pathogen causing systemic infections - up to 50% of the patients infected die as a result. The incidence of such infections is increasing rapidly, especially in hospitalized patients. In New Zealand, such infections are now ten times more frequent than they were 15 years ago.
Moreover, the reservoir of anti-Candida. drugs is very limited, and these agents'can have severe side effects.
E. coli is an ubiquitous bacteria, with a large number of known strains. The particularly nasty E. coli strain E. coli 0157:H7 is a member of the EHEC -enterohemorrhagic E. coll group. Enterohemorrhagic means an intestinally-related organism which causes hemorrhaging - and therefore, loss of blood. E. coli 0157:H7 produces a toxin, called Shiga-like toxin (SLT) or Vero toxin. The toxin is a protein which causes severe damage to intestinal epithelial cells. This condition is particularly dangerous to small children, and may be lethal, as children are too small to tolerate significant blood and fluid loss. In some cases another syndrome is involved which is called hemolytic uremic syndrome (HUS), which is characterized by kidney failure and loss of red blood cells.
Approximately 5% to 10% of children progress to this stage of disease. In severe cases, the disease can cause permanent kidney damage. The presence of this bacterium can also be very dangerous to the elderly or infirm. There can be a combination of HUS and other factors which involve the blood system, which can be lethal to the elderly in 50% of the cases. There is evidence that E. coli 0157:H7 is becoming more prevalent.
Pseudo zonas aeruginosa is a Gram-negative bacterium that is noted for its environmental versatility, ability to cause disease in particularly susceptible individuals, and its resistance to antibiotics. The most serious complication of cystic fibrosis is respiratory tract infection by the ubiquitous bacterium Pseudomonas aeruginosa. Cancer and burn patients also commonly suffer serious infections by this organism, as do certain other individuals with immune systems deficiencies. Unlike many environmental bacteria, P.
aeruginosa has a remarkable capacity to cause disease in susceptible hosts. It has the ability to adapt to and thrive in many ecological niches, from water and soil to plant and animal tissues. The bacterium is capable of utilizing a wide range of organic compounds as food sources, thus giving it an exceptional ability to colonize ecological niches where nutrients are limited. P. aeruginosa can produce a number of toxic proteins which not only cause extensive tissue damage, but also interfere with the human immune system's defense mechanisms. These proteins range from potent toxins that enter and kill host cells at or near the site of colonization to degradative enzymes that permanently disrupt the cell membranes and connective tissues in various organs.
Staphylococcus aureus is a leading cause of soft tissue infections, as well as toxic shock syndrome (TSS) and scalded skin syndrome. The pathogenic effects of Staph are mainly associated with the toxins it produces. Most of these toxins are produced in the stationary phase of the bacterial growth curve. In fact, it is not uncommon for an infected site to contain no viable Staph cells. The S. aureus enterotoxin causes quick onset food poisoning which can lead to cramps and severe vomiting. Infection can be traced to contaminated meats which have not been fully cooked. These microbes also secrete leukocidin, a toxin which destroys white blood cells and leads to the formation of pus and acne.
Particularly, S.
aureus has been found to be the causative agent in such ailments as pneumonia, meningitis, boils, arthritis, and osteomyelitis (chronic bone infection). Most S. aureus are penicillin resistant, but vancomycin and nafcillin are known to be effective against most strains.
The molds such as Aspergillus fumigatus are filamentous fizngi. They are especially prevalent growing on the nonliving organic materials in the soil. They disperse their non-sexual spores called conidia in the air. Most Aspergilli are harmless to humans and A.
fumigatus in particular is harmless to humans whose immune system has not been compromised by disease, drug therapy or genetic conditions. Exposure to A.
fumigatus can cause an allergic response in sensitive individuals. More importantly, A.
fumigatus is an opportunistic pathogen of bone marrow transplant patients, AIDS patients, and other immune compromised individuals.
Aspergillusfumigatus is the most common mold causing infection worldwide. The first infection described in man, an aspergilloma, was reported in Edinburgh in 1842 and many cases of invasive disease in non-immunocompromised patients have been reported.
These cases and more recent epidemiological data emphasize that A. fumigatus is a primary, albeit rare, pathogen of man. Allergic disease due to Aspergillus was first described in London in 1952 and the first invasive (and fatal) infection in an immunocompromised patient was described in 1953 in the British Medical Journal in a patient from Gloucester.
The frequency of invasive disease has risen approximately 14-fold over the 12 years to 1992, as judged after death in unselected autopsies. Invasive aspergillosis has overtaken candidiasis as the most frequent fiun.gal pathogen detected post mortem in tertiary care hospitals in Europe. Thus 4% of all patients dying had invasive aspergillosis, compared with about 2% with invasive candidiasis. Patients at risk based on the disease frequency include those with chronic granulomatous disease (25-40%), lung transplant recipients (17-26%), allogeneic bone marrow transplant patients (4-30%), neutropenic patients with leukemia (5-25%), heart transplant recipients (2-13%), pancreas transplant recipients (1-4%), renal transplant patients in Europe and the USA (- 1%) and in India (-10%), and patients with AIDS, multiple myeloma and severe combined immunodeficiency (-4%). Over 500,000 transplants are performed annually in the world. Acute leukemia affects about 3/100,000 of the population and on average each patient receives 3 cycles of chemotherapy, with each cycle defining a major risk period. Similar incidence is observed for high grade lymphoma patients who are also at high risk of invasive aspergillosis. In the industrialized nations alone these treatment protocols generate about 250,000 periods of major risk per year. AIDS cases are predicted to exceed 40 million by the end of the year 2000 which would result in about 1.4 million cases of invasive aspergillosis, although in developing countries most patients will not live long enough to get this disease.
The crude mortality from invasive aspergillosis is around 85% and falls to around 50% if treated. The new drugs in trial (voriconazole, etc.) may reduce the mortality slightly (-r10%), but patients in trials tend to do better than those treated in clinical practice. In addition to invasive disease, Aspergillus causes a number of other diseases in man. These include aspergilloma ("colonization" of existing pulmonary cavities), sinusitis in normal people, allergic bronchopulmonary and sinus infections, keratitis (which usually leads to blindness in that eye and is common in the developing world) and postoperative infections in immunocompetent patients. Aspergilloma numbers are set to rise dramatically due to the increasing incidence of tuberculosis and such aspergilloma cases are notoriously difficult to treat. Cavities of 2 cm or larger after tuberculosis subsequently develop aspergillomas in 15-20% of patients (in the UK). The 5 year survival of patients with aspergillomas is about 40%. Allergic bronchopulmonary aspergillosis occurs in patients with cystic fibrosis and asthmatics (an increasing number) causing pulmonary fibrosis and death usually within 10 years of diagnosis.
Aspergillus flavus is the etiologic agent in a wide range of infections including mycotoxicoses owing to aflotoxins, hypersensitivity pneumonitis, otitis, sinusitis, and invasive disease. Some reports suggest the disease process may be potentiated by aflotoxins, particularly in the immunocompromised/neutropenic host. The organism is extremely angioinvasive with resultant necrosis and infarction.
C. Prior Art Drug Delivery Techniques Ease of active pharmaceutical agent delivery is a key issue facing pharmaceutical companies that develop and commercialize therapeutic products. An active agent that is readily soluble in water, for example, is not difficult to formulate into a suitable dosage form.
However, formulating poorly water-soluble active agent into suitable dosage forms poses a significant challenge. This is because the human body is a water based system;
thus, as a condition of producing therapeutic activity, a drug must dissolve following administration.
Some poorly water-soluble active agents are never commercialized because they cannot be effectively solubilized, and therefore fail to exhibit acceptable in vivo therapeutic activity. Alternatively, the quantity of poorly water-soluble active agent required to be administered to achieve an acceptable level of therapeutic activity may be too great, given the poor water solubility of the agent, and result in unacceptable toxicity. Even if an active agent is formulated into a liquid, wherein the active agent is solubilized in a solvent, such dosage forms sometimes perform sub-optimally. For example, such dosage forms may have unpredictable properties or induce undesirable side effects.
Prior art methods exist for enhancing active agent solubility. For example, the particle size of the active agent can be reduced, thereby increasing the exposed surface area of the active agent, resulting in increased dissolution rate and greater water solubility. One prior method for particle size reduction is wet milling. This method requires grinding of an active agent with beads made of hard glass, ceramic, porcelain, zirconium oxide, zirconium silicate, polymeric resin, or other suitable substance in a media in which the active agent is poorly soluble, such as water. The active agent is physically converted into much smaller particles that remain suspended in the grinding media. The resultant micron-or nanometer-sized active agent particles can then be isolated from the grinding media by methods such as filtration or centrifugation, and formulated into an appropriate dosage form.
See U.S. Patent Nos. 5,145,684; 5,518,187; 5,862,999; and 5,718,388. The media in which the active agent is ground typically contains one or more compounds that function as a surface stabilizer for the active agent. The surface stabilizers adsorb to the surface of the active agent and act as a steric barrier to active agent particle size growth.
Conventional wet milling techniques therefore produce a "bi-phasic" system in which the stabilized active agent nanoparticles are suspended in the aqueous media.
The nanoparticulate drug delivery technology commercialized by Elan Drug Delivery (King of Prussia, PA) under the trade name NanoCrystal technology, and SkyePharma, plc's Insoluble Drug Delivery (IDD~) technology exemplify such wet milling techniques.
However, wet milling of active agent has drawbacks, principally being the cost of the process. The added cost for formulating a poorly water-soluble active agent into a nanoparticulate composition utilizing wet milling can be prohibitive.
Additionally, amorphous compounds are not amenable to wet milling techniques.
Other known methods of making nanoparticulate active agent compositions include precipitation, homogenization, and super critical fluid methods.
Microprecipitation is a method of preparing stable dispersions of poorly soluble active agents. Such a method comprises dissolving an active agent in a solvent followed by precipitating the active agent out of solution. Homogenization is a technique that does not use milling or grinding media.
Active agent in a liquid media constitutes a process stream propelled into a process zone, which in a Microfluidizer (Microfluidics, Inc.) is called the Interaction Chamber. The geometry of the interaction chamber produces powerful forces of sheer, impaction, and cavitation which are responsible for particle size reduction. U.S. Patent No.
5,510,118 refers to a bi-phasic process using a Microfluidizer resulting in nanoparticulate active agent particles. Finally, supercritical fluid methods of making nanoparticulate active agent compositions comprise dissolving an active agent in a solution. The solution and a supercritical fluid are then co-introduced into a particle formation vessel.
The temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid.
Examples of known supercritical methods of making nanoparticles include International Patent Application No.
thus, as a condition of producing therapeutic activity, a drug must dissolve following administration.
Some poorly water-soluble active agents are never commercialized because they cannot be effectively solubilized, and therefore fail to exhibit acceptable in vivo therapeutic activity. Alternatively, the quantity of poorly water-soluble active agent required to be administered to achieve an acceptable level of therapeutic activity may be too great, given the poor water solubility of the agent, and result in unacceptable toxicity. Even if an active agent is formulated into a liquid, wherein the active agent is solubilized in a solvent, such dosage forms sometimes perform sub-optimally. For example, such dosage forms may have unpredictable properties or induce undesirable side effects.
Prior art methods exist for enhancing active agent solubility. For example, the particle size of the active agent can be reduced, thereby increasing the exposed surface area of the active agent, resulting in increased dissolution rate and greater water solubility. One prior method for particle size reduction is wet milling. This method requires grinding of an active agent with beads made of hard glass, ceramic, porcelain, zirconium oxide, zirconium silicate, polymeric resin, or other suitable substance in a media in which the active agent is poorly soluble, such as water. The active agent is physically converted into much smaller particles that remain suspended in the grinding media. The resultant micron-or nanometer-sized active agent particles can then be isolated from the grinding media by methods such as filtration or centrifugation, and formulated into an appropriate dosage form.
See U.S. Patent Nos. 5,145,684; 5,518,187; 5,862,999; and 5,718,388. The media in which the active agent is ground typically contains one or more compounds that function as a surface stabilizer for the active agent. The surface stabilizers adsorb to the surface of the active agent and act as a steric barrier to active agent particle size growth.
Conventional wet milling techniques therefore produce a "bi-phasic" system in which the stabilized active agent nanoparticles are suspended in the aqueous media.
The nanoparticulate drug delivery technology commercialized by Elan Drug Delivery (King of Prussia, PA) under the trade name NanoCrystal technology, and SkyePharma, plc's Insoluble Drug Delivery (IDD~) technology exemplify such wet milling techniques.
However, wet milling of active agent has drawbacks, principally being the cost of the process. The added cost for formulating a poorly water-soluble active agent into a nanoparticulate composition utilizing wet milling can be prohibitive.
Additionally, amorphous compounds are not amenable to wet milling techniques.
Other known methods of making nanoparticulate active agent compositions include precipitation, homogenization, and super critical fluid methods.
Microprecipitation is a method of preparing stable dispersions of poorly soluble active agents. Such a method comprises dissolving an active agent in a solvent followed by precipitating the active agent out of solution. Homogenization is a technique that does not use milling or grinding media.
Active agent in a liquid media constitutes a process stream propelled into a process zone, which in a Microfluidizer (Microfluidics, Inc.) is called the Interaction Chamber. The geometry of the interaction chamber produces powerful forces of sheer, impaction, and cavitation which are responsible for particle size reduction. U.S. Patent No.
5,510,118 refers to a bi-phasic process using a Microfluidizer resulting in nanoparticulate active agent particles. Finally, supercritical fluid methods of making nanoparticulate active agent compositions comprise dissolving an active agent in a solution. The solution and a supercritical fluid are then co-introduced into a particle formation vessel.
The temperature and pressure are controlled, such that dispersion and extraction of the vehicle occur substantially simultaneously by the action of the supercritical fluid.
Examples of known supercritical methods of making nanoparticles include International Patent Application No.
7 and U.S. Patent No. 6,406,718.
There is a need in the art for drug delivery dosage forms having inherent antibacterial, anti-yeast, anti-fungal, and/or anti-viral properties. In addition, there is a need for compositions having such inherent antibacterial, anti-yeast, anti-fungal, and/or anti-viral properties, and which can be used in the absence of an active agent. The present invention satisfies these needs.
SUMMARY
The invention is directed to nanostructured compositions having antimicrobial, anti-fungal, anti-yeast, and/or anti-viral properties. The compositions comprise at least one oil, at least one surfactant, at least one solvent, and water. Additionally, the compositions can comprise an active agent. The active agent can be useful, for example, as a pharmaceutical, diagnostic, or cosmetic.
Another aspect of the invention is directed to pharmaceutical compositions comprising a nanostructured composition according to the invention, as well as one or more desired pharmaceutically acceptable carriers and/or desired excipients which may include viscosity modifiers, colors, flavoring agents, fragrances, etc.
. One aspect of the invention is directed to a unique active pharmaceutical ingredient nano-structured formulation, which comprises (1) a micelle component, (2) a hydro-alcoholic component, i.e., a mixture of water and water-miscible solvent, (3) an oil-in-water emulsion droplet component, and optionally (4) a solid particle component of an active agent. Any or all of these components may comprise a desired active pharmaceutical, diagnostic, cosmetic, or other active ingredient. Thus the active agent may be in solution, as denoted in components 1 to 3, or it may be in precipitated suspension form, as is the case in component 4.
In one embodiment, when the composition is applied to the skin, the solubilized form travels across the skin and into.deeper dermal layers, such as into the dermis. The other components, such as the micelles, oil fraction, and/or the particulate drug may typically position themselves towards the Stratum corneum of the skin layer. Depending on various physical and chemical properties, certain compounds may position themselves in different layers of epidermis and dermis, while others might permeate directly across the skin.
This composite formulation avoids having to incorporate chemical permeation enhancers that are otherwise necessary to induce transdermal permeation of the active pharmaceutical ingredient.
Another aspect of the invention is directed to a method for preparing the nanostructured compositions of the invention comprising: (a) combining a mixture of at least one oil, at least one solvent, and at least one surfactant (also referred to as a surface stabilizer) to form an emulsion base, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture. If an active agent is to be utilized in the composition, an exemplary method of making the composition comprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
Finally, methods of using the compositions of the invention to treat subjects in need, or as a broad spectrum antimicrobial composition for topical or surface disinfection, are also encompassed by the invention.
There is a need in the art for drug delivery dosage forms having inherent antibacterial, anti-yeast, anti-fungal, and/or anti-viral properties. In addition, there is a need for compositions having such inherent antibacterial, anti-yeast, anti-fungal, and/or anti-viral properties, and which can be used in the absence of an active agent. The present invention satisfies these needs.
SUMMARY
The invention is directed to nanostructured compositions having antimicrobial, anti-fungal, anti-yeast, and/or anti-viral properties. The compositions comprise at least one oil, at least one surfactant, at least one solvent, and water. Additionally, the compositions can comprise an active agent. The active agent can be useful, for example, as a pharmaceutical, diagnostic, or cosmetic.
Another aspect of the invention is directed to pharmaceutical compositions comprising a nanostructured composition according to the invention, as well as one or more desired pharmaceutically acceptable carriers and/or desired excipients which may include viscosity modifiers, colors, flavoring agents, fragrances, etc.
. One aspect of the invention is directed to a unique active pharmaceutical ingredient nano-structured formulation, which comprises (1) a micelle component, (2) a hydro-alcoholic component, i.e., a mixture of water and water-miscible solvent, (3) an oil-in-water emulsion droplet component, and optionally (4) a solid particle component of an active agent. Any or all of these components may comprise a desired active pharmaceutical, diagnostic, cosmetic, or other active ingredient. Thus the active agent may be in solution, as denoted in components 1 to 3, or it may be in precipitated suspension form, as is the case in component 4.
In one embodiment, when the composition is applied to the skin, the solubilized form travels across the skin and into.deeper dermal layers, such as into the dermis. The other components, such as the micelles, oil fraction, and/or the particulate drug may typically position themselves towards the Stratum corneum of the skin layer. Depending on various physical and chemical properties, certain compounds may position themselves in different layers of epidermis and dermis, while others might permeate directly across the skin.
This composite formulation avoids having to incorporate chemical permeation enhancers that are otherwise necessary to induce transdermal permeation of the active pharmaceutical ingredient.
Another aspect of the invention is directed to a method for preparing the nanostructured compositions of the invention comprising: (a) combining a mixture of at least one oil, at least one solvent, and at least one surfactant (also referred to as a surface stabilizer) to form an emulsion base, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture. If an active agent is to be utilized in the composition, an exemplary method of making the composition comprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
Finally, methods of using the compositions of the invention to treat subjects in need, or as a broad spectrum antimicrobial composition for topical or surface disinfection, are also encompassed by the invention.
Both the foregoing general description and the following brief description of the drawings and detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P.
aeruginosa (ATCC
9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), and A. niger (ATCC
16404)).
Figure 2 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according the protocol specified in USP 25, <51>, pp. 1869-1871, but with additional microorganisms (P. aeruginosa ATCC
13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus).
Figure 3 shows the results of antibacterial effectiveness testing for estradiol compositions of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC
6538), C.
albicans (ATCC 10231), andA. niger (ATCC 16404)).
Figure 4 shows the results of antibacterial effectiveness testing for testosterone compositions of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC
6538), C. albzcans (ATCC 10231), andA. niger (ATCC 16404)).
Figure 5 shows the estradiol particle size in a nanostructured composition following homogenization.
Figure 6 shows the estradiol particle size in a nanostructured composition following the Silverson Method.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P.
aeruginosa (ATCC
9027), S. aureus (ATCC 6538), C. albicans (ATCC 10231), and A. niger (ATCC
16404)).
Figure 2 shows the results of antibacterial effectiveness testing for a placebo composition (i.e., lacking an active agent) of the invention conducted according the protocol specified in USP 25, <51>, pp. 1869-1871, but with additional microorganisms (P. aeruginosa ATCC
13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus).
Figure 3 shows the results of antibacterial effectiveness testing for estradiol compositions of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC
6538), C.
albicans (ATCC 10231), andA. niger (ATCC 16404)).
Figure 4 shows the results of antibacterial effectiveness testing for testosterone compositions of the invention conducted according to the protocol specified in USP 25, <51>, pp. 1869-1871 (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC
6538), C. albzcans (ATCC 10231), andA. niger (ATCC 16404)).
Figure 5 shows the estradiol particle size in a nanostructured composition following homogenization.
Figure 6 shows the estradiol particle size in a nanostructured composition following the Silverson Method.
Figure 7 shows the testosterone particle size in a nanostructured composition following homogenization.
DETAILED DESCRIPTION
A. Overview of the Invention The invention is directed to nanostructured compositions that surprisingly have antimicrobial, anti-fungal, anti-yeast, and/or anti-viral properties. The nanostructured compositions of the invention comprise at least one solvent, at least one oil, at least one surface stabilizer (also referred to as a surfactant), and aqueous medium. The compositions additionally may comprise oine or more active agents, which may be dissolved or dispersed in any one of the oil, solvent, or water. The active agent can be useful, for example, as a pharmaceutical or cosmetic. No external antibacterial agent or preservative is required to be added to the compositions of the invention to impart the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties.
The compositions of the invention meet the Antimicrobial Effectiveness Testing criteria as described in the United States Pharmacopoeia (USP - General Chapters, Section 51). This is demonstrated by the testing described in Example 4 below, in which various microbes were cultured in the presence of a composition according to the invention (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C.
albicans (ATCC 10231), A. niger (ATCC 16404), P. aeruginosa (ATCC 13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus). The results of the testing are also shown in Figure 1, which graphically shows the dramatic antimicrobial properties of the compositions of the invention.
The standard USP testing requires evaluation in five microorganisms:
Aspergillus niger (ATCC 16404), Candida albicans (ATCC 10231), Escherichia coli (ATCC
8739), Pseudomonas aeruginosa (ATCC 9027) and Staphylococcus aureus (ATCC 6538).
Additional strains were used to confirm the anti-microbial effectiveness in A.
flavus, A.
fumigatus, P aeruginosa (ATCC 25619) and P. aeruginosa (ATCC 13388). As shown in Figure 2, which graphically shows the results of this testing, antimicrobial effectiveness in these additional strains confirm beyond doubt that the composition vehicle itself is antimicrobial.
Moreover, the incorporation of an active agent does not compromise the antimicrobial effectiveness of the compositions of the invention. Specifically, as shown in Examples 3 and 4, compositions of the invention comprising estradiol and testosterone also exhibited significant antimicrobial effects, and satisfied the USP testing requirements for demonstrating antimicrobial activity. See also Figures 3 and 4.
The compositions of the invention are particularly useful in products used for topical treatment of infections, wound healing, etc., as in addition to the pharmacologic properties of the active agent in such compositions, the vehicle itself acts as a microbicidal agent. Such a composition possibly induces synergistic action and reduces the possibility of development of drug resistance microorganisms. Moreover, such a composition may enable the use of lower doses of the active agent.
At present, various types of cosmetic and pharmaceutical compositions require the addition of an antimicrobial agent to retard microbial growth. Choosing the right antimicrobial agent can be challenging due to potential interactions between the active agent and the antimicrobial agent. Moreover, the antimicrobial agent can be toxic and it can induce adverse reactions in patients.
In one embodiment of the invention, the compositions comprise an active agent, and the active agent is selected from the group consisting of, but not limited to fenofibrate, estradiol, alendronic acid, acyclovir, paclitaxel, and cyclosporine.
In another embodiment, the oil is selected from the group consisting of, but not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), and wheat germ oil.
In one embodiment, the solvent is selected from the group consisting of, but not limited to isopropyl myristate, triacetin, N-methyl pyrrolidinone, aliphatic and aromatic alcohols, polyethylene glycols, and propylene glycol. Other examples of useful solvents are long-chain alcohols. Ethyl alcohol and benzyl alcohol are yet other examples of alcohols that may be used in the present invention.
In yet another embodiment, the stabilizer or surfactant is selected from the group consisting of, but not limited to, sorbitan esters, glycerol esters, polyethylene glycol esters, block polymers, acrylic polymers (such as Pernuleno'), ethoxylated fatty esters (such as Cremophoro RH-40), ethoxylated alcohols (such as Brij ), ethoxylated fatty acids (such as Tween 20), monoglycerides, silicon based surfactants,.and polysorbates. In a further embodiment, the sorbitan ester stabilizer is Span or Arlacel ; the glycerol ester is glycerin monostearate; the polyethylene glycol ester is polyethylene glycol stearate;
the block polymer is a Pluronic ; the acrylic polymer is Pemulen ; the ethoxylated fatty ester is Cremophor RH-40; the ethoxylated alcohol is Brij ; the ethoxylated fatty acid is Tween 20, or a combination thereof.
In another embodiment, a homogenizing step is performed via a high-pressure system at 1,000 to 40,000 psi.
In one embodiment, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 10 microns.
In other embodiments of the invention, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 rim, less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 rim, less than about 1300 nm, less than about 1200 rim, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm, less than about 90 nm, less than about 80 nm, less than about 70 nm, less than about 60 nm, less than about 50 nm, less than about 40 nm, less than about 30 nm, less than about 20 nm, or less than about 10 nm. In one embodiment, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 3 microns in diameter.
Three methods of making the compositions of the invention are described. The first method does not require the presence of an active agent. In this method, at least one oil, at least one solvent, and at least one surfactant are combined to form an emulsion base, water is added to the emulsion base, and (c) the mixture is homogenized or vigorously stirred.
If an active agent is to be utilized in the composition, an exemplary method of making the composition cornprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
Two specific methods for making active agent compositions of the invention are described. In the first method ("Route I"), active agent is milled (i.e., homogenized or vigorously stirred to reduce the particle size of the active agent) in an emulsion base. This method requires that the active agent is poorly soluble or insoluble in all phases of the oil phase/lipophilic phase and the water or buffer. In the second method ("Route Il"), simultaneous milling (i.e., homogenizing or vigorously stirring to reduce the particle size of the active agent) and precipitation of the active agent in an emulsion base is observed. The second method requires that the active agent is soluble or partially soluble in one or more phases of the emulsion base; i.e., that the active agent is soluble in an oil, solvent, or water or buffer.
One benefit of the methods of making the compositions of the invention as compared to prior art methods, such as wet milling, is that the methods are applicable to water-soluble active agent as well as poorly water soluble active agent. Another benefit of the methods of the invention is that they do not require grinding media or specialized grinding process or equipments. The use of such grinding media can add cost and complexity to a particle size reduction process for an active agent. Yet another benefit of the methods of the invention is that it can be used to process amorphous agents.
For Route I, an active agent is first suspended in a mixture of a non-miscible liquid, such as an oil, solvent, and water or buffer to form an emulsion base, followed by homogenization or vigorous stirring of the emulsion base. Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High velocity homogenization or vigorous stirring, producing forces of high shear and cavitation, are preferred. High shear processes are preferred as low shear processes can result in larger active agent particle sizes. The resultant composition is a composite mixture of active agent suspended in the emulsion droplet (nano-emulsion fraction) and sterically stabilized microcrystalline and/or nanocrystalline active agent in the media. This tri-phasic system comprises particulate drug, oil, and water or buffer. The resultant micro/nano-particulate active agent has an effective average particle size of less than about 3 microns. Smaller particulate active agent can also be obtained, as described below.
The active agent can be precipitated out from the oil droplets by adding more of the non-miscible liquid. The precipitated active agent typically has an effective average particle size of less than about 3 microns. If desired, the active agent particles can be prevented from aggregating or clumping together by incorporating a surfactant or emulsifier, i.e., a "surface stabilizer."
Route II is utilized for an active agent that is soluble in at least one part of the emulsion base, such as the solvent. For Route II, an active agent is dissolved in a mixture of oil, solvent, and stabilizer to form an emulsion pre-mix. The active agent remains in soluble form if water or buffer is not added to the mixture. Upon the addition of water or buffer and the application of shear forces, the active agent is precipitated into micro/nanoparticles having an effective average particle size of less than about 3 microns.
Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High energy input, through high velocity homogenization or vigorous stirring, is a preferred process. The high energy processes reduce the size of the emulsion droplets, thereby exposing a large surface area to the surrounding aqueous environment. High shear processes are preferred, as low shear processes can result in larger particle sizes. This is followed by precipitation of nanoparticulate active agent previously embedded in the emulsion base. The end product comprises active agent in solution and particulate suspension, both distributed between the solvent, oil, and water or buffer. In one embodiment, nanoparticulate active agent has at least one surface stabilizer associated with the surface thereof.
Examples of active agent that are poorly water soluble in water but soluble in another liquid include estradiol, which is soluble in ethanol, and fenofibrate, which is freely soluble in 1-methyl-2-pyrrolidone or N-methyl-pyrrolidinone [NMP], slightly soluble in oil and stabilizer, and insoluble in water.
If desired, the water miscible oil droplets and active agent nanoparticles prepared using Route I or Route II can be filtered through either a 0.2 or 0.45 micron filter. Larger oil droplets and/or active agent particles can be created by simply increasing the water content, decreasing the oil-stabilizer-solvent content, or changing the shear in forming the oil droplets.
For the emulsion base used as an antimicrobial composition, or used in Route I
or Route II as a drug delivery vehicle, the preferred ratio of oil:stabilizer:solvent is about 23:
about 5: about 4, respectively, on a weight-to-weight basis. The preferred ratio of the oil comprising phase to water or buffer is about 2: about 1, respectively. In other embodiments of the invention, the oil may be present at about 5% to about 50% (w/w); the solvent may be present at about 0.5% to about 10% (w/w); the stabilizer or surfactant may be present at about 0.5% to about 10% (w/w), the water may be present at about 20% to about 80 %
(w/w), or any combination thereof.
B. Compositions of the Invention The methods of the invention can produce several different types of compositions. A
first composition comprises: (1) at least one oil; (2) at least one solvent;
(3) at least one surfactant or surface stabilizer; and (4) water. This composition exhibits broad spectrum antimicrobial activity and, therefore, the composition can be used as a general purpose disinfectant.
Other types of compositions according to the invention comprise at least one active agent. For example, a second composition can comprise: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer;
(2) water or a buffer;
(3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil and optionally at least one solvent; and optionally (4) microparticulate active agent. The microparticulate active agent can be the same as or different from the nanoparticulate active agent. The particulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof. Such a composition is made utilizing Route I.
A third composition comprises: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer; (2) water or buffer;
and (3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil, optionally at least one solvent, and solubilized active agent. The composition may additionally comprise microparticulate active agent. The solubilized active agent can be present in the water or buffer, oil, solvent, or a combination thereof. In addition, nanoparticulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof. Such a composition is made utilizing Route II. In a further embodiment of the invention, the solubilized active agent can be precipitated out from the emulsion droplets. The precipitated active agent preferably has an effective average particle size of less than about 3 microns.
The tri-phasic compositions of the invention are beneficial for several reasons. First, formulations resulting from the Route II method comprise both solid and solubilized forms of the same active agent. This enables a resultant pharmaceutical formulation to provide both immediate release and controlled release of the component active agent, providing for fast onset of activity combined with prolonged activity of the active agent.
Moreover, when formulated for topical application to the skin, in a cream or lotion for example, the solid active agent nanoparticles may provide an immediate local therapeutic effect at the skin surface, while the solubilized active agent within the emulsion base crosses the skin/cell barrier allowing the active agent to enter the body's system.
That is, the solubilized active agent crosses the skin rapidly and penetrates into deeper layers, whereas the solid part does not permeate into deeper skin layers, but acts as local depot and as a reservoir for supplying drug into deeper layers. Hence, a formulation comprising both active agent nanoparticles and solubilized active agent can provide local and systemic therapeutic effects, which are particularly beneficial for transdermal dosage forms.
The different components of the two types of compositions described above can be separated and, if desired, used independently.
This invention permits many different types of active agents to be formulated into emulsion-based formulations. Examples of such active agents include, but are not limited to, acyclovir, cyclosporine, estradiol, fenofibrate, ceterizine, nicotine, naltrexone, and alendronic acid.
1. Active Agent Nanoparticles The solid active agent nanoparticles can be separated from the aqueous suspension media and/or the emulsion globules, for instance, by filtration or centrifugation. This provides a convenient method of obtaining nanoparticles of a poorly water-soluble or water-insoluble active agent. Furthermore, when a surface stabilizer is included in the particle size reduction process, it prevents the active agent nanoparticles from aggregating and, therefore, the active agent nanoparticles are stabilized at a nanoparticulate size. If desired, the active agent nanoparticles can then be formulated into any suitable dosage form.
Active agent nanoparticles can be made using food grade, USP or NF grade materials suitable for human use applications.
Exemplary dosage forms include, but are not limited to, liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups. Moreover, the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof. The compositions of the invention may be formulated for delivery via any suitable method, such as for parenteral injection (i.e., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, otic, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
Since the active agent nanoparticles have an effective average particle size of less than about 3 microns, the particles typically are more readily able to move across absorption barriers, such as skin, as compared to microcrystalline active agent.
Similarly, the small active agent particle size enables passage through blood/tissue and blood/tumor barriers of various organs.
2. Emulsion Globules Comprising Active Agent Nanoparticles and/or Solubilized Active Agent The emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can also be isolated, if desired, from the surrounding aqueous or buffer phase and used in therapeutic dosage fonns. The emulsion globules can be made using food grade, USP or NF grade materials suitable for human use applications.
Nanoparticulate oil globules comprising solubilized active agent, and methods of making the same, are described in U.S. Patent No. 5,629,021 ("the `021 patent"), which is incorporated herein by reference. The emulsion globules of the invention typically comprise: (1) at least one oil; (2) at least one solvent; (3) at least one surface stabilizer or surfactant; and optionally (4) solubilized active agent, particulate active agent, or a combination thereof. Emulsion globules comprising solubilized active agent, particulate active agent, or a combination thereof can be isolated, if desired, for example, by filtration. Emulsion globules comprising solubilized active agent are particularly suitable vehicles for transporting active agent across the skin barrier and into the blood. Hence, globules comprising solubilized active agent offer a systemic way to administer active agent to an individual.
In general, the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof have diameters of about 10 to about 1000 nm, and comprise a significant quantity of active agent, with a mean a diameter of less than about 1 micron preferred, and with the smallest globules filterable through a 0.2 micron filter, such as is typically used for microbiological purification. The range of active agent concentration in the globules can be from about 1% to about 50%. The emulsion globules can be stored at between about 20 to about 40 C. In one embodiment of the invention, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%
of the globules in the preparation have diameters of less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nrn, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nrn.
By varying different parameters of Route I and Route II, the size and integrity of such globules can be modified. Hence, the stability of globules comprising dissolved active agent can be altered to enable the release of active agent, either as a solution or precipitate. This is a microreservoir-dissolution-controlled system, where the drug solids acts as depot and, as the solubilized fraction is depleted, more drug is drawn into solution form the particulate depot. Thus, the emulsion globules comprising solubilized active agent enable controlled active agent release over time.
The small size of the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof and their compatibility with tissue render them applicable to numerous uses. For example, the emulsion globules are useful as topical drug delivery vehicles as they enable rapid dermal penetration. The globules are also exceptionally versatile in that the active agent utilized can be any active agent that is suspendable or dissolvable in any of the water or buffer, oil, or solvent. These properties allow this system to be used with active agents that are difficult to formulate for use in other delivery systems.
In addition, the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can be diluted with aqueous solutions without stability loss. This enables the use of high active agent concentration, i.e.
up to about 30%, products which can be diluted for use as necessary. The concentration of active agent, however, depends on the solubility of the actual drug and the amount of solvent used to dissolve it.
In one embodiment of the invention, the emulsion globules comprise as an active agent estradiol, acyclovir, or testosterone and are formulated into a dosage form for transdermal delivery.
C. Components of the Methods and Compositions of the Invention 1. Active Pharmaceutical Ingredient a. Properties Any suitable active agent may be employed in the compositions and methods of the invention. For an active agent to be utilized in the Route I method, the active agent must be poorly soluble, or insoluble, in all phases of the milling (i.e., homogenization or vigorously stirring) system, including water and the solvent and oil to be used in the method. For an active agent to be utilized in Route II, the active agent must be poorly water soluble, or water insoluble, but soluble in at least one phase of the emulsion base, such as the oil or solvent and stabilizer or stabilizer solution.
By "poorly water-soluble" or "water insoluble" it is meant that the active agent has a solubility in water of less than about than about 20 mg/mL, less than about 10 mg/mL, less than about 1 mg/mL, less than about 0.1 mg/mL, less than about 0.01 mg/mL, or less than about 0.001 mg/mL at ambient temperature and pressure and at about pH 7.
The active agent to be used in the methods of the invention, and present in the compositions of the invention, can be amorphous, semi-amorphous, crystalline, semi-crystalline, or a mixture thereof.
b. Active Agent Particle Size As used herein, active agent particle size is determined on the basis of the weight average particle size as measured by conventional techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, laser diffraction, or disk centrifugation.
As used herein, "nanoparticulate active agent" refers to active agent having an effective average particle size of less than about 3 microns.
"microcrystalline active agent"
refers to active agent having an effective average particle size of greater than about 3 microns.
As used herein, an "effective average particle size" for an active agent is the size below which about 50% of the active agent particles fall. Thus, if the effective average particle size is less than about 3 microns, at least 50% of the active agent particles in the composition have a size of less than about 3 microns. In other embodiments of the invention, the effective average particle size of the active agent particles in the compositions of the invention can be less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 mn, less than about 2300 nm, less than about 2200 mn, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than about 1800 mu, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 mn, less than about 1300 mn, less than about 1200 nm, less than about 1100 nm, less than about 1000 mn, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm.
In other embodiments of the invention, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% of the active agent particles have a size less than the effective average, i.e., less than about 3 microns, less than about 2900 nm, less than about 2800 mn, etc.
c. Exemplary Active Agents Any suitable active agent may be used in the methods and compositions of the invention. Examples of classes of useful active agent include, but are not limited to, therapeutic and diagnostic agents, pigments, paints, inks, dyes, photographic materials, cosmetic ingredients, etc.
Amphiphile-type active agents may be incorporated into the present formulations.
That is, drugs or therapeutic compounds that can be ionized and are soluble in polar or non-polar solvents may be incorporated in the formulations of the present invention. Such compounds are soluble, therefore, both in oil and aqueous environments (amphiphiles).
Examples of such compounds include nicotine and ceterizine_ Hydrophilic active agents also may be incorporated into a formulation of the present invention. Such compounds include, but are not limited to naltrexone hydrochloride, alendronic acid, and ceterizine dihydrochloride.
The active agent may be a hormone, such as testosterone, progesterone, and estrogen.
Other hormones include: (1) Amine-derived hormones, such as catecholamines, adrenaline (or epinephrine), dopamine, noradrenaline (or norepinephrine), tryptophan derivatives, melatonin (N-acetyl-5-methoxytryptamine), serotonin (5-HT), tyrosine derivatives, thyroxine (T4), triiodothyronine (T3); (2) peptide hormones, such as antimullerian hormone (AMH, also mullerian inhibiting factor or hormone), adiponectin (also Acrp30), adrenocorticotropic hormone (ACTH, also corticotropin), angiotensinogen and angiotensin, antidiuretic hormone (ADH, also vasopressin, arginine vasopressin, AVP), atrial-natriuretic peptide (ANP, also atriopeptin), Calcitonin, cholecystokinin (CCK), corticotropin-releasing hormone (CRH), erythropoietin (EPO), follicle-stimulating hormone (FSH), gastrin, glucagons, gonadotropin-releasing hormone (GnRH), growth hormone-releasing hormone (GHRH), human chorionic gonadotropin (hCG), growth hormone (GH or hGH), insulin, insulin-like growth factor (IGF, also somatomedin), leptin, luteinizing hormone (LH), melanocyte stimulating hormone (MSH
or a-MSH), neuropeptide Y, oxytocin, parathyroid hormone (PTH), prolactin (PRL), relaxin, rennin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone (TSH), thyrotropin-releasing hormone (TRH); (3) steroid hormones, such as glucocorticoids, cortisol, mineralocorticoids, aldosterone, sex steroids, androgens, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione, dihydrotestosterone (DHT), Estrogens, estradiol, Progestagens, progesterone, Progestins, (4) sterol hormones, such as vitamin D derivatives and calcitriol, (5) lipid and phospholipid hormones (eicosanoids) such as prostaglandins, leukotrienes, prostacyclin, and thromboxane.
In one embodiment of the invention, therefore, the active agent is estradiol, fenofibrate, acyclovir, alendronic acid, or testosterone. Specific examples of active agents that may be utilized in the methods of the invention include, but are not limited to, insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein, betaserori, erythropoietin, alpha interferon, beta interferon, gamma interferon, somatropin, somatotropin, somastostatin, insulin-like growth factor, luteinizing hormone releasing hormone, factor VIII, interleukins, interleukin analogues, hematological agents, anticoagulants, hematopoietic agents, hemostatics, thrombolytic agents, endocrine agents, antidiabetic agents, antithyroid agents, beta-adrenoceptor blocking agents, growth hormones, growth hormone releasing hormone, sex hormones, thyroid agents, parathyroid calcitonin, bisphosphonates, uterine-active agents, cardiovascular agents, antiarrhythmic agents, anti-anginal agents, anti-hypertensive agents, vasodilators, agents used in treatment of heart disorders, cardiac inotropic agents, renal agents, genitourinary agents, antidiuretic agents, respiratory agents, antihistamines, cough suppressants, parasympathomimetics, sympathomimetics, xanthines, central nervous system agents, analgesics, anesthetics, anti-emetic agents, anorexiants, antidepressants, anti-migraine agents, antiepileptics, dopaminergics, anticholinergics, antiparkinsonian agents, muscle relaxants, narcotic antagonists, sedatives, stimulants, treatments for attention deficit disorder, methylphenidate, fluoxamine, bisolperol, tacrolimus, sacrolimus, cyclosporine, gastrointestinal agents, systemic anti-infectives, agents used in the treatment of AIDS, anthelmintics, antimycobacterial agents, immunologic agents, vaccines, hormones; dermatological agents including, anti-inflammatory agents, elastase inhibitors, antimuscarinic agents, lipid regulating agents, blood products, blood substitutes, antineoplastic agents including, leuprolide acetate, chemotherapy agents, oncology therapies, nutrients, nutritional agents, chelating agents, interleukin-2, IL-1 ra, heparin, hirudin, colony stimulating factors, tissue plasminogen activator, oxytocin, nitroglycerine, diltiazem, clonidine, nifedipine, verapamil, isosorbide-5-mononitrate, organic nitrates, diuretics, desmopressin, vasopressin, expectorants, mucolytics, fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxymorphone, methadone, lidocaine, bupivacaine, diclofenac, naproxen, paverin, scopolamine, ondansetron, domperidone, metoclopramide, sumatriptan, ergot alkaloids, benzodiazepines, phenothiozines, prostaglandins antibiotics, anti-viral agents, anti-fungals, immunosuppressants, anti-allergic agents, astringents, corticosteroids fluorouracil, bleomycin, vincristine, or deferoxamine. The active agent may be useful in the treatment of wound-healing.
2. Oils For both the methods of Route I and Route II and the compositions of the invention, any suitable oil can be used. Exemplary oils that can be used include, for example, vegetable oils, nut oils, fish oils, lard oil, mineral oils, squalane, tricaprylin, and mixtures thereof.
Specific examples of oils that may be used include, but are not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), wheat germ oil, and mixtures thereof.
3. Surface Stabilizers or Surfactants The compositions of the invention also comprise at least-one surface stabilizer or surfactant. When the compositions additionally comprise a nanoparticulate active agent, the surface stabilizer used in the methods and compositions of the invention associates with, or adsorbs to, the surface of the nanoparticulate active agent, but does not covalently bind to the active agent. The surface stabilizer is preferably soluble in water. One or more surface stabilizers may be used in the compositions and methods of the invention. As used herein, the terms "stabilizer", "surface stabilizer", and "surfactant" are used interchangeably.
Any suitable nonionic or ionic surfactant may be utilized in the compositions of the invention, including anionic, cationic, and zwitterionic surfactants.
Exemplary stabilizers or surfactants that may be used in the compositions of the invention lacking an active agent, and in active agent comprising compositions of the invention, include but are not limited to, non-phospholipid surfactants, such as the Tween (polyoxyethylene derivatives of sorbitan fatty acid esters) family of surfactants (i.e., Tween 20, Tween 60, and Tween 80), nonphenol polyethylene glycol ethers, sorbitan esters (such as Span and Arlacel ), glycerol esters (such as glycerin monostearate), polyethylene glycol esters (such as polyethylene glycol stearate), block polymers (such as Pluronics'll), acrylic polymers (such as Pemulen ), ethoxylated fatty esters (such as Cremophor RH-40), ethoxylated alcohols (such as Brij ), ethoxylated fatty acids, monoglycerides, silicon based surfactants, polysorbates, and Tergitol (Poly(oxy-1,2-ethanediyl), a -(4-nonylphenol)-.omega.-hydroxy, branched [molecular weight average 1980]), and Tergitol NP-70 (a mixed surfactant--AQ=70%).
4. Solvents Any suitable solvent can be used in the methods and compositions of the invention.
Exemplary solvents include, but are not limited, to isopropyl myristate, triacetin, N-methyl pyrrolidinone, long-chain alcohols, polyethylene glycols, propylene glycol, diethyleneglycol monoethyl ether, and long- and short-chain alcohols, such as ethanol. Other short chain alcohols and/or amides may be used, as well as aliphatic and aromatic alcohols, such as benzyl alchohol. Mixtures of solvents can also be used in the compositions and methods of the invention.
5. Water or Buffer If the methods and/or compositions of the invention use or comprise water or a buffer, the aqueous solution is preferably a physiologically compatible solution such as water or phosphate buffered saline.
6. Other Ingredients A number of other materials may be added to the compositions of the invention.
Volatile oils, such as volatile flavor oils, can be used in lieu of some of the oil or can be added in addition to the primary oil. Exemplary volatile oils or fragrances that can be utilized in the invention include, but are not limited to, balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, origanum oil, and peppermint oil. A
coloring agent, such as a food coloring agent can also be used. Exemplary food colors that can be utilized in the compositions of the invention include, but are not limited to, green, yellow, red, and blue.
The food colors utilized are food grade materials (McCormick), although materials from other sources can be substituted. In addition, a flavoring extract can be used in the methods and compositions of the invention. Exemplary flavored extracts include, but are not limited to, pure anise extract (73% alcohol), imitation banana extract (40% ethanol), imitation cherry extract (24% ethanol), chocolate extract (23% ethanol), pure lemon extract (84% ethanol), pure orange extract (80% ethanol), pure peppermint extract (89% ethanol), imitation pineapple extract (42% ethanol), imitation rum extract (35% ethanol), imitation strawberry extract (30% ethanol), and pure or imitation vanilla extract (35% ethanol).
Typically, the extracts utilized are food grade materials (McCormick), although materials from other sources can be substituted.
D. Methods of Using the Compositions_of the Invention The compositions of the invention are useful as a broad spectrum antimicrobial agent.
They can be used for topical or surface disinfection, for example, of biological and non-biological surfaces. The compositions can be used to disinfect surfaces likely to be exposed to microbes, such as cooking surfaces, eating surfaces, any surface in a hospital, areas exposed to young children, etc. Biological surfaces include skin, hair, mucous membranes, wound surfaces, insect bites, etc.
The compositions can also be used as delivery vehicles for an active agent, such as a drug or cosmetic. The compositions avoid the requirement of adding a antimicrobial agent to retard microbial growth. When formulated into a dosage form for administration to a mammal, such as a human, the compositions of the invention can be administered to a subject via any conventional means. The compositions can be useful in the formulation of active agents intended to treat wounds and would surfaces. Some of these active agents are not compatible with typical antimicrobial agents. Therefore, a vehicle that is inherently antimicrobial may be an ideal delivery system.
As used herein, the term "subject" is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably. In addition, the compositions of the invention can be formulated into any suitable dosage form, such as liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups. Moreover, the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof.
The compositions of the invention may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
Liquid dosage forms include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active agent, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
"Therapeutically effective amount" as used herein with respect to an active agent dosage shall mean that dosage that provides the specific pharmacological response for which the active agent is administered in a significant number of subjects in need of such treatment.
It is emphasized that "therapeutically effective amount," administered to a particular subject in a particular instance may not be effective for 100% of patients treated for a specific disease, and will not always be effective in treating the diseases described herein, even though such dosage is deemed a"therapeutically effective amount" by those skilled in the art.
One of ordinary skill will appreciate that effective amounts of an active agent can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of an active agent in the compositions of the invention may be varied to obtain an amount of the active agent that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered active agent, the desired duration of treatment, and other factors.
Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available document, including a U.S. patent, are specifically incorporated by reference.
EXAMPLES
Example 1 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, soybean oil, and Polysorbate 80 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer.
The quantities of each component are shown below in Table 1.
Ingredient Quantity Ethyl Alcohol USP 8.8 gm Polysorbate 80 NF 9.4 gm Soybean oil USP 50.2 gm Water USP 31.7 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Polysorbate 80 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 2 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention comprising the active agent estradiol.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17beta -diol.
The molecular formula of estradiol is C18H2402 and the structural formula is:
-=r" ~ .
OH
The molecular weight of estradiol is 272.39.
Current U.S. Food and Drug Administration (FDA) approved estradiol products include oral pills (Estinyl , Estrace , Gynodiol , Oveon 35 ), transdermal patches (Climarat , Vivelle , Estraderm'8'), a vaginal ring (Estring"'), and a topical emulsion (Estxasorb ). The drug is used in hormone replacement therapy, to treat moderate to severe symptoms of hot flashes and night sweats associated with menopause and to prevent pregnancy.
Estradiol was dissolved in ethanol. The oil and Polysorbate 80 were added to the estradiol solution, water was added to the estradiol/ethyl alcohol/oil/Polysorbate 80 mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 2A.
Ingredient Quantity Estradiol 0.25 Ethyl Alcohol USP 8.8 gm Polysorbate 80 NF 9.4 m Soybean oil USP 50.2 gm Water USP 31.7 m The composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes. The particle size of the composition is detailed in Table 2B below and is further represented in Figure 5.
Table 2B
Mean ( m) Standard Deviation m 0.0826 0.048 Alternatively, estradiol can be dissolved in ethyl alcohol, the oil and water can be added to the estradiol solution, and water can be added to the resulting composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for minutes).
The particle size of the composition according to the Silverson method is detailed in Table 2C below and is further represented in Figure 6.
15 Table 2C
Mean (pm) Standard Deviation m 1.204 0.930 The resulting composition can be used directly as an estradiol topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 3 The piurpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention comprising the active agent testosterone.
Testosterone USP is a white to practically white crystalline powder chemically described as 17-beta hydroxyandrost-4-en-3-one.
H3.O H
OH
H H
Testosterone It has the chemical formula C19H2802 and a molecular weight of 288.42.
Testosterone is commercially available, for example, in a injectable dosage forms, transdermal gel (AndroGel , Testim8'), transdermal delivery device (Androdermo, Testoderm ), and a buccal drug delivery system (Striant ). Testosterone is used, for example, in hormone replacement therapy.
Testosterone was dissolved in ethyl alcohol. Oil and Polysorbate 80 were added to the testosterone solution, and water was added to the resulting composition.
The resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 3A.
Ingredient Quantity Testosterone 3.09 m Ethyl Alcohol USP 8.8 Polysorbate 80 NF 9.4 gm Soybean oil USP 50.2 gm Water USP 31.7 gm The testosterone/ethyl alcohol/oil/Polysorbate 80/water composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes. The particle size of the composition is detailed in Table 3B below and is further represented in Figure 7.
Table 3B
Mean ( m) Standard Deviation (ttm) 1.052 0.507 Alternatively, the testosterone can be dissolved in ethyl alcohol, and oil and the Polysorbate 80 can be added to the testosterone solution. Water can be added to the testosterone/ethyl alcohol/oil/Polysorbate 80 composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a testosterone topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Examnle 4 The purpose of this example was to determine the effect of concentration of excipients on the antimicrobial properties of the formulation. The composition of Example I
was diluted with water by 10-fold and tested for antimicrobial effectiveness.
The quantities of each component are shown below in Table 4 Ingredient Quantity Ethyl Alcohol USP 0.88 gm Polysorbate 80-NF 0.94 gm Soybean oil USP 5.02 gm Water USP 93.16 This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards. The resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
Example 5 The purpose of this example was as yet another example to determine the effect of concentration of excipients on the antimicrobial properties of the formulation. The composition of Example 1 was diluted with water by 50-fold and tested for antimicrobial properties.
The quantities of each component are shown below in Table 4 Ingredient Quantity Eth 1 Alcohol USP 0.18 gm Polysorbate 80 NF 0.19 gm So bean oil USP 1.0 gm Water USP 98.63 gm This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards. The resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
Example 6 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, soybean oil, and Pluronic F-68 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer.
The quantities of each component are shown below in Table 6.
ln redient Quantity Eth l Alcohol USP 8.8 gm Pluronic F-68 6.0 gm So bean oil USP 50.2 gm Water USP 35.0 m The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 7 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, benzyl alcohol, isopropyl myristate, light mineral oil, and Pluronic F-68 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 7.
Ingredient Quantity Ethyl Alcohol USP 10.6 Benzyl Alcohol 5.3 gm Pluronic F-68 7.4 gm Iso ro l Myristate 5.3 gm Light Mineral Oil 40.4 Water USP 30.9 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV- 1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 8 The purpose of this example was to describe preparation of a nanostructured composition that included propofol, a model active pharmaceutical ingredient, and that did not meet the USP Antimicrobial Effectiveness Testing standards.
Propofol, Ethyl alcohol, soybean oil, and Polysorbate 80 were mixed together.
Saline was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 8.
Ingredient uanti Propofol 1.0 gm Ethyl Alcohol USP 0.5 gm Polysorbate 80 NF 0.9 Soybean oil USP 4.5 Saline 93.1 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards.
Example 9 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 1.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as described in Example 1 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida Albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), Staphylococcus aureus (bacteria), Aspergillus fumigatus (fungus), and Aspergillus flavus (fungus).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of the organisms shown below in Table 4. The quantity of inoculum of the composition prepared as in Example 1 for each test is shown in Table 4, below. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation, at day 7, day 14, and at day 28. The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results of the tests are shown in Table 4. In addition, the results are graphically shown in Figure 1 and 2.
~'^~Qc~=~ o~ o A~ cn A~ tw~A~ on~
~--~ O q y o O~ O o O~ O O U
0~ Q~' N O^+V "Cl O"d TJ ~
00 U ~ Z V A V A Z O V I !~ Rdp.
L`t eA
.~ ..
C~ U U
(:N U .-O. d0 4, .~0. bA R.-O. OD a vi o -~ o A0 an =a A`~ oo r s A~ on C) N ^O,~ U y O c.a O r=O,~ U
O G O c~ d' "RC O ~ ~f' 'UR
V A VA ~.' Z V A
U bA a p d4 a~ b0 R
o~ o A`~ on~A~ ao aA~ ao Q O O ~
O O Oi~ ~td p~oet'7 O~ ~Y 'RU ?
N U N f-+ V A e7-+ V A I.N.
'cl ta U 0 2 OA a~ bD a~ bA a w o o ~ on'~A~ oo A~ oo=o ~
O r' '~! 'd O"' ~? C O
m 'U O
r"A
V A V d=
.~ p0 b ^CS 'LS ~
kn -~f=i CS U O ~ ~~ p a~i ~~ p~'~. 0 N
A~lo o A Uo+ o~
v-d ob o vv =~ ~ ~ ~ ~ z v n v n v n eG O ~ Cp v +- Ur E-1 3õ" ~ bA R O CU a~ bA a et ~Zi '~o U
o o A~ on'~A~ an A~ oq.o 0 U o~ o a~ " o o c~ o y o c W ~F=+ o~ o cso-- ~ o~ ~ ao~ o ~
ao , r.~ as c a ,_.; o--~ er zs --+ d b o- v v peLC~ '~ cv v w V V A 2 E" ..r ba v ~ ~U
o O
b q a~oi bA a a aD a E-+
~V o o en a U O~ O N v U y U.-~i v N V V =x=
E'~ O O a O.'"' R R O R
O d" "C O -" 'LS
v~i v rn Z V n P.' Z V h~ Z VA w y bA N d N
U c~ U
e.Hy+ ~ a'~ o A`r'o o~ A O o~ A O o~
O^'rY'C O^' d T! p N V Z V A Z V A Z V A
w Y K a bA
.~ U o ';"~+ a ~ a a "' U er o 0 ao ew cn o '.
0 C) o`~ o 0 0 0 0 0 ~ o 0 o na b o~
t~~' ~
~ C) .-~ .-~ ~-Ni N=-r .~. t~ c'~) I~i .~ ~
V
ci = N
O
H R, " o A A A
The results dramatically demonstrate the surprising effectiveness of the compositions of the invention as antibacterial, antifungal, and anti-yeast agents. For all but one tested organism (A. niger), all organisms were eradicated after 7 days, and for A.
niger, the growth of the organism was drastically diminished, with only 70 cfu/g measured on Day 28.
Moreover, the results demonstrate that the composition meets the USP 25 requirements for Antimicrobial Effectiveness Test.
Example 10 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 2, to determine if the addition of an active agent such as estradiol affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention. This example also evaluates the effect on antimicrobial activity of varying the quantity of alcohol present in the compositions of the invention.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of the organisms shown below in Table 5. The quantity of inoculum of the composition prepared as described in Example 2 for each test is shown in Table 5, below. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation, at day 14 (Table 5) and day 28 Table 6). The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results of the tests are shown in Tables 5 and 6. In addition, the results are graphically shown in Figure 3.
TABLE 5: Antimicrobial Effectiveness Test for Estradiol-Comprising Composition Day 14 Results Or anism A. niger C. albicans E. coli P. aeruginosa S. aureus Strain #
Inoculum 200,000 cfu/mL 250,000 cfu/mL 550,000 cfu/mL 220,000 cfu/mL 580,000 cfu/mL
per mL
12roduct % EtOH
7.7% 30,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 lo reduction > 4 lo reduction 7.3% 17,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 efu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7.4% 17,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfulg > 4 lo reduction > 4 log reduction > 4 log reduction > 4 log reduction 7.0% 13,000 cfu/g None Detected None Detected None Detected None Detected I log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction TABLE 6: Antimicrobial Effectiveness Test for Estradiol-Comprising Composition Day 28 Results Organism A. niger C. albicans E. coli P. aeruginosa S. aureus Strain #
Inoculum 200,000 cfu/mL 250,000 cfu/mL 550,000 cfu/mL 220,000 cfu/mL 580,000 cfu/mL
per mL
product % EtOH
7,7"/u None Detected None Detected None Detected None Detected None Detected <100 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g >3 log reduction > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7,3% None Detected None Detected None Detected None Detected None Detected <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7,4% 180 cfu/g None Detected None Detected None Detected None Detected 3.2 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 lo reduction > 4 log reduction > 4 log reduction > 4 lo reduction 7,0% 100,000 cfu/g None Detected 180 cfu/g None Detected None Detected 0.5 log reduction <10 cfu/g 3.6 log reduction <10 cfu/g <l 0 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction Example 11 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 3, to determine if the addition of an active agent such as testosterone affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of A. niger, C. albicans, E.
coli, P. aeruginosa, and S. aureus. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation and at day 7, 14, and 28. The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results, shown in Figure 4, dramatically demonstrate the surprising effectiveness of the compositions of the invention as antibacterial, anti-fungal, and anti-yeast agents when the compositions are used as drug delivery vehicles.
Surprisingly, the presence of an active agent does not negate the antimicrobial effects of the compositions of the invention. Moreover, the results demonstrate that the composition meets the USP 25 requirements for Antimicrobial Effectiveness Test.
It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
DETAILED DESCRIPTION
A. Overview of the Invention The invention is directed to nanostructured compositions that surprisingly have antimicrobial, anti-fungal, anti-yeast, and/or anti-viral properties. The nanostructured compositions of the invention comprise at least one solvent, at least one oil, at least one surface stabilizer (also referred to as a surfactant), and aqueous medium. The compositions additionally may comprise oine or more active agents, which may be dissolved or dispersed in any one of the oil, solvent, or water. The active agent can be useful, for example, as a pharmaceutical or cosmetic. No external antibacterial agent or preservative is required to be added to the compositions of the invention to impart the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties.
The compositions of the invention meet the Antimicrobial Effectiveness Testing criteria as described in the United States Pharmacopoeia (USP - General Chapters, Section 51). This is demonstrated by the testing described in Example 4 below, in which various microbes were cultured in the presence of a composition according to the invention (testing with E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C.
albicans (ATCC 10231), A. niger (ATCC 16404), P. aeruginosa (ATCC 13388), P. aeruginosa (ATCC 25619) A. flavus, and A. fumigatus). The results of the testing are also shown in Figure 1, which graphically shows the dramatic antimicrobial properties of the compositions of the invention.
The standard USP testing requires evaluation in five microorganisms:
Aspergillus niger (ATCC 16404), Candida albicans (ATCC 10231), Escherichia coli (ATCC
8739), Pseudomonas aeruginosa (ATCC 9027) and Staphylococcus aureus (ATCC 6538).
Additional strains were used to confirm the anti-microbial effectiveness in A.
flavus, A.
fumigatus, P aeruginosa (ATCC 25619) and P. aeruginosa (ATCC 13388). As shown in Figure 2, which graphically shows the results of this testing, antimicrobial effectiveness in these additional strains confirm beyond doubt that the composition vehicle itself is antimicrobial.
Moreover, the incorporation of an active agent does not compromise the antimicrobial effectiveness of the compositions of the invention. Specifically, as shown in Examples 3 and 4, compositions of the invention comprising estradiol and testosterone also exhibited significant antimicrobial effects, and satisfied the USP testing requirements for demonstrating antimicrobial activity. See also Figures 3 and 4.
The compositions of the invention are particularly useful in products used for topical treatment of infections, wound healing, etc., as in addition to the pharmacologic properties of the active agent in such compositions, the vehicle itself acts as a microbicidal agent. Such a composition possibly induces synergistic action and reduces the possibility of development of drug resistance microorganisms. Moreover, such a composition may enable the use of lower doses of the active agent.
At present, various types of cosmetic and pharmaceutical compositions require the addition of an antimicrobial agent to retard microbial growth. Choosing the right antimicrobial agent can be challenging due to potential interactions between the active agent and the antimicrobial agent. Moreover, the antimicrobial agent can be toxic and it can induce adverse reactions in patients.
In one embodiment of the invention, the compositions comprise an active agent, and the active agent is selected from the group consisting of, but not limited to fenofibrate, estradiol, alendronic acid, acyclovir, paclitaxel, and cyclosporine.
In another embodiment, the oil is selected from the group consisting of, but not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), and wheat germ oil.
In one embodiment, the solvent is selected from the group consisting of, but not limited to isopropyl myristate, triacetin, N-methyl pyrrolidinone, aliphatic and aromatic alcohols, polyethylene glycols, and propylene glycol. Other examples of useful solvents are long-chain alcohols. Ethyl alcohol and benzyl alcohol are yet other examples of alcohols that may be used in the present invention.
In yet another embodiment, the stabilizer or surfactant is selected from the group consisting of, but not limited to, sorbitan esters, glycerol esters, polyethylene glycol esters, block polymers, acrylic polymers (such as Pernuleno'), ethoxylated fatty esters (such as Cremophoro RH-40), ethoxylated alcohols (such as Brij ), ethoxylated fatty acids (such as Tween 20), monoglycerides, silicon based surfactants,.and polysorbates. In a further embodiment, the sorbitan ester stabilizer is Span or Arlacel ; the glycerol ester is glycerin monostearate; the polyethylene glycol ester is polyethylene glycol stearate;
the block polymer is a Pluronic ; the acrylic polymer is Pemulen ; the ethoxylated fatty ester is Cremophor RH-40; the ethoxylated alcohol is Brij ; the ethoxylated fatty acid is Tween 20, or a combination thereof.
In another embodiment, a homogenizing step is performed via a high-pressure system at 1,000 to 40,000 psi.
In one embodiment, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 10 microns.
In other embodiments of the invention, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, less than about 3 microns, less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 rim, less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 rim, less than about 1300 nm, less than about 1200 rim, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm, less than about 90 nm, less than about 80 nm, less than about 70 nm, less than about 60 nm, less than about 50 nm, less than about 40 nm, less than about 30 nm, less than about 20 nm, or less than about 10 nm. In one embodiment, the active agent particles, droplets comprising active agent, or a combination thereof have a mean particle size of less than about 3 microns in diameter.
Three methods of making the compositions of the invention are described. The first method does not require the presence of an active agent. In this method, at least one oil, at least one solvent, and at least one surfactant are combined to form an emulsion base, water is added to the emulsion base, and (c) the mixture is homogenized or vigorously stirred.
If an active agent is to be utilized in the composition, an exemplary method of making the composition cornprises: (a) adding the active agent to a mixture of oil, solvent, and surfactant or stabilizer to form an emulsion base, wherein the active agent is soluble in either or both of oil and solvent, but is not soluble in water, (b) adding water to the emulsion base, and (c) homogenizing or vigorously stirring the mixture.
Two specific methods for making active agent compositions of the invention are described. In the first method ("Route I"), active agent is milled (i.e., homogenized or vigorously stirred to reduce the particle size of the active agent) in an emulsion base. This method requires that the active agent is poorly soluble or insoluble in all phases of the oil phase/lipophilic phase and the water or buffer. In the second method ("Route Il"), simultaneous milling (i.e., homogenizing or vigorously stirring to reduce the particle size of the active agent) and precipitation of the active agent in an emulsion base is observed. The second method requires that the active agent is soluble or partially soluble in one or more phases of the emulsion base; i.e., that the active agent is soluble in an oil, solvent, or water or buffer.
One benefit of the methods of making the compositions of the invention as compared to prior art methods, such as wet milling, is that the methods are applicable to water-soluble active agent as well as poorly water soluble active agent. Another benefit of the methods of the invention is that they do not require grinding media or specialized grinding process or equipments. The use of such grinding media can add cost and complexity to a particle size reduction process for an active agent. Yet another benefit of the methods of the invention is that it can be used to process amorphous agents.
For Route I, an active agent is first suspended in a mixture of a non-miscible liquid, such as an oil, solvent, and water or buffer to form an emulsion base, followed by homogenization or vigorous stirring of the emulsion base. Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High velocity homogenization or vigorous stirring, producing forces of high shear and cavitation, are preferred. High shear processes are preferred as low shear processes can result in larger active agent particle sizes. The resultant composition is a composite mixture of active agent suspended in the emulsion droplet (nano-emulsion fraction) and sterically stabilized microcrystalline and/or nanocrystalline active agent in the media. This tri-phasic system comprises particulate drug, oil, and water or buffer. The resultant micro/nano-particulate active agent has an effective average particle size of less than about 3 microns. Smaller particulate active agent can also be obtained, as described below.
The active agent can be precipitated out from the oil droplets by adding more of the non-miscible liquid. The precipitated active agent typically has an effective average particle size of less than about 3 microns. If desired, the active agent particles can be prevented from aggregating or clumping together by incorporating a surfactant or emulsifier, i.e., a "surface stabilizer."
Route II is utilized for an active agent that is soluble in at least one part of the emulsion base, such as the solvent. For Route II, an active agent is dissolved in a mixture of oil, solvent, and stabilizer to form an emulsion pre-mix. The active agent remains in soluble form if water or buffer is not added to the mixture. Upon the addition of water or buffer and the application of shear forces, the active agent is precipitated into micro/nanoparticles having an effective average particle size of less than about 3 microns.
Nanoparticles can be produced with reciprocating syringe instrumentation, continuous flow instrumentation, or high speed mixing equipment. High energy input, through high velocity homogenization or vigorous stirring, is a preferred process. The high energy processes reduce the size of the emulsion droplets, thereby exposing a large surface area to the surrounding aqueous environment. High shear processes are preferred, as low shear processes can result in larger particle sizes. This is followed by precipitation of nanoparticulate active agent previously embedded in the emulsion base. The end product comprises active agent in solution and particulate suspension, both distributed between the solvent, oil, and water or buffer. In one embodiment, nanoparticulate active agent has at least one surface stabilizer associated with the surface thereof.
Examples of active agent that are poorly water soluble in water but soluble in another liquid include estradiol, which is soluble in ethanol, and fenofibrate, which is freely soluble in 1-methyl-2-pyrrolidone or N-methyl-pyrrolidinone [NMP], slightly soluble in oil and stabilizer, and insoluble in water.
If desired, the water miscible oil droplets and active agent nanoparticles prepared using Route I or Route II can be filtered through either a 0.2 or 0.45 micron filter. Larger oil droplets and/or active agent particles can be created by simply increasing the water content, decreasing the oil-stabilizer-solvent content, or changing the shear in forming the oil droplets.
For the emulsion base used as an antimicrobial composition, or used in Route I
or Route II as a drug delivery vehicle, the preferred ratio of oil:stabilizer:solvent is about 23:
about 5: about 4, respectively, on a weight-to-weight basis. The preferred ratio of the oil comprising phase to water or buffer is about 2: about 1, respectively. In other embodiments of the invention, the oil may be present at about 5% to about 50% (w/w); the solvent may be present at about 0.5% to about 10% (w/w); the stabilizer or surfactant may be present at about 0.5% to about 10% (w/w), the water may be present at about 20% to about 80 %
(w/w), or any combination thereof.
B. Compositions of the Invention The methods of the invention can produce several different types of compositions. A
first composition comprises: (1) at least one oil; (2) at least one solvent;
(3) at least one surfactant or surface stabilizer; and (4) water. This composition exhibits broad spectrum antimicrobial activity and, therefore, the composition can be used as a general purpose disinfectant.
Other types of compositions according to the invention comprise at least one active agent. For example, a second composition can comprise: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer;
(2) water or a buffer;
(3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil and optionally at least one solvent; and optionally (4) microparticulate active agent. The microparticulate active agent can be the same as or different from the nanoparticulate active agent. The particulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof. Such a composition is made utilizing Route I.
A third composition comprises: (1) nanoparticulate active agent having associated with the surface thereof at least one surface stabilizer; (2) water or buffer;
and (3) an emulsion pre-mix or oil phase or lipophilic phase comprising at least one oil, optionally at least one solvent, and solubilized active agent. The composition may additionally comprise microparticulate active agent. The solubilized active agent can be present in the water or buffer, oil, solvent, or a combination thereof. In addition, nanoparticulate active agent can be present in the water or buffer, oil, solvent, or a combination thereof. Such a composition is made utilizing Route II. In a further embodiment of the invention, the solubilized active agent can be precipitated out from the emulsion droplets. The precipitated active agent preferably has an effective average particle size of less than about 3 microns.
The tri-phasic compositions of the invention are beneficial for several reasons. First, formulations resulting from the Route II method comprise both solid and solubilized forms of the same active agent. This enables a resultant pharmaceutical formulation to provide both immediate release and controlled release of the component active agent, providing for fast onset of activity combined with prolonged activity of the active agent.
Moreover, when formulated for topical application to the skin, in a cream or lotion for example, the solid active agent nanoparticles may provide an immediate local therapeutic effect at the skin surface, while the solubilized active agent within the emulsion base crosses the skin/cell barrier allowing the active agent to enter the body's system.
That is, the solubilized active agent crosses the skin rapidly and penetrates into deeper layers, whereas the solid part does not permeate into deeper skin layers, but acts as local depot and as a reservoir for supplying drug into deeper layers. Hence, a formulation comprising both active agent nanoparticles and solubilized active agent can provide local and systemic therapeutic effects, which are particularly beneficial for transdermal dosage forms.
The different components of the two types of compositions described above can be separated and, if desired, used independently.
This invention permits many different types of active agents to be formulated into emulsion-based formulations. Examples of such active agents include, but are not limited to, acyclovir, cyclosporine, estradiol, fenofibrate, ceterizine, nicotine, naltrexone, and alendronic acid.
1. Active Agent Nanoparticles The solid active agent nanoparticles can be separated from the aqueous suspension media and/or the emulsion globules, for instance, by filtration or centrifugation. This provides a convenient method of obtaining nanoparticles of a poorly water-soluble or water-insoluble active agent. Furthermore, when a surface stabilizer is included in the particle size reduction process, it prevents the active agent nanoparticles from aggregating and, therefore, the active agent nanoparticles are stabilized at a nanoparticulate size. If desired, the active agent nanoparticles can then be formulated into any suitable dosage form.
Active agent nanoparticles can be made using food grade, USP or NF grade materials suitable for human use applications.
Exemplary dosage forms include, but are not limited to, liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups. Moreover, the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof. The compositions of the invention may be formulated for delivery via any suitable method, such as for parenteral injection (i.e., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, otic, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
Since the active agent nanoparticles have an effective average particle size of less than about 3 microns, the particles typically are more readily able to move across absorption barriers, such as skin, as compared to microcrystalline active agent.
Similarly, the small active agent particle size enables passage through blood/tissue and blood/tumor barriers of various organs.
2. Emulsion Globules Comprising Active Agent Nanoparticles and/or Solubilized Active Agent The emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can also be isolated, if desired, from the surrounding aqueous or buffer phase and used in therapeutic dosage fonns. The emulsion globules can be made using food grade, USP or NF grade materials suitable for human use applications.
Nanoparticulate oil globules comprising solubilized active agent, and methods of making the same, are described in U.S. Patent No. 5,629,021 ("the `021 patent"), which is incorporated herein by reference. The emulsion globules of the invention typically comprise: (1) at least one oil; (2) at least one solvent; (3) at least one surface stabilizer or surfactant; and optionally (4) solubilized active agent, particulate active agent, or a combination thereof. Emulsion globules comprising solubilized active agent, particulate active agent, or a combination thereof can be isolated, if desired, for example, by filtration. Emulsion globules comprising solubilized active agent are particularly suitable vehicles for transporting active agent across the skin barrier and into the blood. Hence, globules comprising solubilized active agent offer a systemic way to administer active agent to an individual.
In general, the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof have diameters of about 10 to about 1000 nm, and comprise a significant quantity of active agent, with a mean a diameter of less than about 1 micron preferred, and with the smallest globules filterable through a 0.2 micron filter, such as is typically used for microbiological purification. The range of active agent concentration in the globules can be from about 1% to about 50%. The emulsion globules can be stored at between about 20 to about 40 C. In one embodiment of the invention, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%
of the globules in the preparation have diameters of less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nrn, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nrn.
By varying different parameters of Route I and Route II, the size and integrity of such globules can be modified. Hence, the stability of globules comprising dissolved active agent can be altered to enable the release of active agent, either as a solution or precipitate. This is a microreservoir-dissolution-controlled system, where the drug solids acts as depot and, as the solubilized fraction is depleted, more drug is drawn into solution form the particulate depot. Thus, the emulsion globules comprising solubilized active agent enable controlled active agent release over time.
The small size of the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof and their compatibility with tissue render them applicable to numerous uses. For example, the emulsion globules are useful as topical drug delivery vehicles as they enable rapid dermal penetration. The globules are also exceptionally versatile in that the active agent utilized can be any active agent that is suspendable or dissolvable in any of the water or buffer, oil, or solvent. These properties allow this system to be used with active agents that are difficult to formulate for use in other delivery systems.
In addition, the emulsion globules comprising solubilized active agent, active agent nanoparticles, or a combination thereof can be diluted with aqueous solutions without stability loss. This enables the use of high active agent concentration, i.e.
up to about 30%, products which can be diluted for use as necessary. The concentration of active agent, however, depends on the solubility of the actual drug and the amount of solvent used to dissolve it.
In one embodiment of the invention, the emulsion globules comprise as an active agent estradiol, acyclovir, or testosterone and are formulated into a dosage form for transdermal delivery.
C. Components of the Methods and Compositions of the Invention 1. Active Pharmaceutical Ingredient a. Properties Any suitable active agent may be employed in the compositions and methods of the invention. For an active agent to be utilized in the Route I method, the active agent must be poorly soluble, or insoluble, in all phases of the milling (i.e., homogenization or vigorously stirring) system, including water and the solvent and oil to be used in the method. For an active agent to be utilized in Route II, the active agent must be poorly water soluble, or water insoluble, but soluble in at least one phase of the emulsion base, such as the oil or solvent and stabilizer or stabilizer solution.
By "poorly water-soluble" or "water insoluble" it is meant that the active agent has a solubility in water of less than about than about 20 mg/mL, less than about 10 mg/mL, less than about 1 mg/mL, less than about 0.1 mg/mL, less than about 0.01 mg/mL, or less than about 0.001 mg/mL at ambient temperature and pressure and at about pH 7.
The active agent to be used in the methods of the invention, and present in the compositions of the invention, can be amorphous, semi-amorphous, crystalline, semi-crystalline, or a mixture thereof.
b. Active Agent Particle Size As used herein, active agent particle size is determined on the basis of the weight average particle size as measured by conventional techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, laser diffraction, or disk centrifugation.
As used herein, "nanoparticulate active agent" refers to active agent having an effective average particle size of less than about 3 microns.
"microcrystalline active agent"
refers to active agent having an effective average particle size of greater than about 3 microns.
As used herein, an "effective average particle size" for an active agent is the size below which about 50% of the active agent particles fall. Thus, if the effective average particle size is less than about 3 microns, at least 50% of the active agent particles in the composition have a size of less than about 3 microns. In other embodiments of the invention, the effective average particle size of the active agent particles in the compositions of the invention can be less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 mn, less than about 2300 nm, less than about 2200 mn, less than about 2100 nm, less than about 2000 nm, less than about 1900 nm, less than about 1800 mu, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 mn, less than about 1300 mn, less than about 1200 nm, less than about 1100 nm, less than about 1000 mn, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, or less than about 100 nm.
In other embodiments of the invention, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% of the active agent particles have a size less than the effective average, i.e., less than about 3 microns, less than about 2900 nm, less than about 2800 mn, etc.
c. Exemplary Active Agents Any suitable active agent may be used in the methods and compositions of the invention. Examples of classes of useful active agent include, but are not limited to, therapeutic and diagnostic agents, pigments, paints, inks, dyes, photographic materials, cosmetic ingredients, etc.
Amphiphile-type active agents may be incorporated into the present formulations.
That is, drugs or therapeutic compounds that can be ionized and are soluble in polar or non-polar solvents may be incorporated in the formulations of the present invention. Such compounds are soluble, therefore, both in oil and aqueous environments (amphiphiles).
Examples of such compounds include nicotine and ceterizine_ Hydrophilic active agents also may be incorporated into a formulation of the present invention. Such compounds include, but are not limited to naltrexone hydrochloride, alendronic acid, and ceterizine dihydrochloride.
The active agent may be a hormone, such as testosterone, progesterone, and estrogen.
Other hormones include: (1) Amine-derived hormones, such as catecholamines, adrenaline (or epinephrine), dopamine, noradrenaline (or norepinephrine), tryptophan derivatives, melatonin (N-acetyl-5-methoxytryptamine), serotonin (5-HT), tyrosine derivatives, thyroxine (T4), triiodothyronine (T3); (2) peptide hormones, such as antimullerian hormone (AMH, also mullerian inhibiting factor or hormone), adiponectin (also Acrp30), adrenocorticotropic hormone (ACTH, also corticotropin), angiotensinogen and angiotensin, antidiuretic hormone (ADH, also vasopressin, arginine vasopressin, AVP), atrial-natriuretic peptide (ANP, also atriopeptin), Calcitonin, cholecystokinin (CCK), corticotropin-releasing hormone (CRH), erythropoietin (EPO), follicle-stimulating hormone (FSH), gastrin, glucagons, gonadotropin-releasing hormone (GnRH), growth hormone-releasing hormone (GHRH), human chorionic gonadotropin (hCG), growth hormone (GH or hGH), insulin, insulin-like growth factor (IGF, also somatomedin), leptin, luteinizing hormone (LH), melanocyte stimulating hormone (MSH
or a-MSH), neuropeptide Y, oxytocin, parathyroid hormone (PTH), prolactin (PRL), relaxin, rennin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone (TSH), thyrotropin-releasing hormone (TRH); (3) steroid hormones, such as glucocorticoids, cortisol, mineralocorticoids, aldosterone, sex steroids, androgens, testosterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione, dihydrotestosterone (DHT), Estrogens, estradiol, Progestagens, progesterone, Progestins, (4) sterol hormones, such as vitamin D derivatives and calcitriol, (5) lipid and phospholipid hormones (eicosanoids) such as prostaglandins, leukotrienes, prostacyclin, and thromboxane.
In one embodiment of the invention, therefore, the active agent is estradiol, fenofibrate, acyclovir, alendronic acid, or testosterone. Specific examples of active agents that may be utilized in the methods of the invention include, but are not limited to, insulin, calcitonin, calcitonin gene regulating protein, atrial natriuretic protein, betaserori, erythropoietin, alpha interferon, beta interferon, gamma interferon, somatropin, somatotropin, somastostatin, insulin-like growth factor, luteinizing hormone releasing hormone, factor VIII, interleukins, interleukin analogues, hematological agents, anticoagulants, hematopoietic agents, hemostatics, thrombolytic agents, endocrine agents, antidiabetic agents, antithyroid agents, beta-adrenoceptor blocking agents, growth hormones, growth hormone releasing hormone, sex hormones, thyroid agents, parathyroid calcitonin, bisphosphonates, uterine-active agents, cardiovascular agents, antiarrhythmic agents, anti-anginal agents, anti-hypertensive agents, vasodilators, agents used in treatment of heart disorders, cardiac inotropic agents, renal agents, genitourinary agents, antidiuretic agents, respiratory agents, antihistamines, cough suppressants, parasympathomimetics, sympathomimetics, xanthines, central nervous system agents, analgesics, anesthetics, anti-emetic agents, anorexiants, antidepressants, anti-migraine agents, antiepileptics, dopaminergics, anticholinergics, antiparkinsonian agents, muscle relaxants, narcotic antagonists, sedatives, stimulants, treatments for attention deficit disorder, methylphenidate, fluoxamine, bisolperol, tacrolimus, sacrolimus, cyclosporine, gastrointestinal agents, systemic anti-infectives, agents used in the treatment of AIDS, anthelmintics, antimycobacterial agents, immunologic agents, vaccines, hormones; dermatological agents including, anti-inflammatory agents, elastase inhibitors, antimuscarinic agents, lipid regulating agents, blood products, blood substitutes, antineoplastic agents including, leuprolide acetate, chemotherapy agents, oncology therapies, nutrients, nutritional agents, chelating agents, interleukin-2, IL-1 ra, heparin, hirudin, colony stimulating factors, tissue plasminogen activator, oxytocin, nitroglycerine, diltiazem, clonidine, nifedipine, verapamil, isosorbide-5-mononitrate, organic nitrates, diuretics, desmopressin, vasopressin, expectorants, mucolytics, fentanyl, sufentanil, butorphanol, buprenorphine, levorphanol, morphine, hydromorphone, hydrocodone, oxymorphone, methadone, lidocaine, bupivacaine, diclofenac, naproxen, paverin, scopolamine, ondansetron, domperidone, metoclopramide, sumatriptan, ergot alkaloids, benzodiazepines, phenothiozines, prostaglandins antibiotics, anti-viral agents, anti-fungals, immunosuppressants, anti-allergic agents, astringents, corticosteroids fluorouracil, bleomycin, vincristine, or deferoxamine. The active agent may be useful in the treatment of wound-healing.
2. Oils For both the methods of Route I and Route II and the compositions of the invention, any suitable oil can be used. Exemplary oils that can be used include, for example, vegetable oils, nut oils, fish oils, lard oil, mineral oils, squalane, tricaprylin, and mixtures thereof.
Specific examples of oils that may be used include, but are not limited to, almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), wheat germ oil, and mixtures thereof.
3. Surface Stabilizers or Surfactants The compositions of the invention also comprise at least-one surface stabilizer or surfactant. When the compositions additionally comprise a nanoparticulate active agent, the surface stabilizer used in the methods and compositions of the invention associates with, or adsorbs to, the surface of the nanoparticulate active agent, but does not covalently bind to the active agent. The surface stabilizer is preferably soluble in water. One or more surface stabilizers may be used in the compositions and methods of the invention. As used herein, the terms "stabilizer", "surface stabilizer", and "surfactant" are used interchangeably.
Any suitable nonionic or ionic surfactant may be utilized in the compositions of the invention, including anionic, cationic, and zwitterionic surfactants.
Exemplary stabilizers or surfactants that may be used in the compositions of the invention lacking an active agent, and in active agent comprising compositions of the invention, include but are not limited to, non-phospholipid surfactants, such as the Tween (polyoxyethylene derivatives of sorbitan fatty acid esters) family of surfactants (i.e., Tween 20, Tween 60, and Tween 80), nonphenol polyethylene glycol ethers, sorbitan esters (such as Span and Arlacel ), glycerol esters (such as glycerin monostearate), polyethylene glycol esters (such as polyethylene glycol stearate), block polymers (such as Pluronics'll), acrylic polymers (such as Pemulen ), ethoxylated fatty esters (such as Cremophor RH-40), ethoxylated alcohols (such as Brij ), ethoxylated fatty acids, monoglycerides, silicon based surfactants, polysorbates, and Tergitol (Poly(oxy-1,2-ethanediyl), a -(4-nonylphenol)-.omega.-hydroxy, branched [molecular weight average 1980]), and Tergitol NP-70 (a mixed surfactant--AQ=70%).
4. Solvents Any suitable solvent can be used in the methods and compositions of the invention.
Exemplary solvents include, but are not limited, to isopropyl myristate, triacetin, N-methyl pyrrolidinone, long-chain alcohols, polyethylene glycols, propylene glycol, diethyleneglycol monoethyl ether, and long- and short-chain alcohols, such as ethanol. Other short chain alcohols and/or amides may be used, as well as aliphatic and aromatic alcohols, such as benzyl alchohol. Mixtures of solvents can also be used in the compositions and methods of the invention.
5. Water or Buffer If the methods and/or compositions of the invention use or comprise water or a buffer, the aqueous solution is preferably a physiologically compatible solution such as water or phosphate buffered saline.
6. Other Ingredients A number of other materials may be added to the compositions of the invention.
Volatile oils, such as volatile flavor oils, can be used in lieu of some of the oil or can be added in addition to the primary oil. Exemplary volatile oils or fragrances that can be utilized in the invention include, but are not limited to, balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, origanum oil, and peppermint oil. A
coloring agent, such as a food coloring agent can also be used. Exemplary food colors that can be utilized in the compositions of the invention include, but are not limited to, green, yellow, red, and blue.
The food colors utilized are food grade materials (McCormick), although materials from other sources can be substituted. In addition, a flavoring extract can be used in the methods and compositions of the invention. Exemplary flavored extracts include, but are not limited to, pure anise extract (73% alcohol), imitation banana extract (40% ethanol), imitation cherry extract (24% ethanol), chocolate extract (23% ethanol), pure lemon extract (84% ethanol), pure orange extract (80% ethanol), pure peppermint extract (89% ethanol), imitation pineapple extract (42% ethanol), imitation rum extract (35% ethanol), imitation strawberry extract (30% ethanol), and pure or imitation vanilla extract (35% ethanol).
Typically, the extracts utilized are food grade materials (McCormick), although materials from other sources can be substituted.
D. Methods of Using the Compositions_of the Invention The compositions of the invention are useful as a broad spectrum antimicrobial agent.
They can be used for topical or surface disinfection, for example, of biological and non-biological surfaces. The compositions can be used to disinfect surfaces likely to be exposed to microbes, such as cooking surfaces, eating surfaces, any surface in a hospital, areas exposed to young children, etc. Biological surfaces include skin, hair, mucous membranes, wound surfaces, insect bites, etc.
The compositions can also be used as delivery vehicles for an active agent, such as a drug or cosmetic. The compositions avoid the requirement of adding a antimicrobial agent to retard microbial growth. When formulated into a dosage form for administration to a mammal, such as a human, the compositions of the invention can be administered to a subject via any conventional means. The compositions can be useful in the formulation of active agents intended to treat wounds and would surfaces. Some of these active agents are not compatible with typical antimicrobial agents. Therefore, a vehicle that is inherently antimicrobial may be an ideal delivery system.
As used herein, the term "subject" is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably. In addition, the compositions of the invention can be formulated into any suitable dosage form, such as liquid dispersions, oral suspensions, tablets, gels, aerosols, ointments, creams, capsules, dry powders, multiparticulates, sprinkles, sachets, lozenges, and syrups. Moreover, the dosage forms of the invention may be solid dosage forms, liquid dosage forms, semi-liquid dosage forms, immediate release formulations, modified release formulations, controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, or any combination thereof.
The compositions of the invention may also comprise adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
Liquid dosage forms include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active agent, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
"Therapeutically effective amount" as used herein with respect to an active agent dosage shall mean that dosage that provides the specific pharmacological response for which the active agent is administered in a significant number of subjects in need of such treatment.
It is emphasized that "therapeutically effective amount," administered to a particular subject in a particular instance may not be effective for 100% of patients treated for a specific disease, and will not always be effective in treating the diseases described herein, even though such dosage is deemed a"therapeutically effective amount" by those skilled in the art.
One of ordinary skill will appreciate that effective amounts of an active agent can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of an active agent in the compositions of the invention may be varied to obtain an amount of the active agent that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered active agent, the desired duration of treatment, and other factors.
Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available document, including a U.S. patent, are specifically incorporated by reference.
EXAMPLES
Example 1 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, soybean oil, and Polysorbate 80 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer.
The quantities of each component are shown below in Table 1.
Ingredient Quantity Ethyl Alcohol USP 8.8 gm Polysorbate 80 NF 9.4 gm Soybean oil USP 50.2 gm Water USP 31.7 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Polysorbate 80 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 2 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention comprising the active agent estradiol.
Estradiol is chemically described as estra-1,3,5(10)-triene-3,17beta -diol.
The molecular formula of estradiol is C18H2402 and the structural formula is:
-=r" ~ .
OH
The molecular weight of estradiol is 272.39.
Current U.S. Food and Drug Administration (FDA) approved estradiol products include oral pills (Estinyl , Estrace , Gynodiol , Oveon 35 ), transdermal patches (Climarat , Vivelle , Estraderm'8'), a vaginal ring (Estring"'), and a topical emulsion (Estxasorb ). The drug is used in hormone replacement therapy, to treat moderate to severe symptoms of hot flashes and night sweats associated with menopause and to prevent pregnancy.
Estradiol was dissolved in ethanol. The oil and Polysorbate 80 were added to the estradiol solution, water was added to the estradiol/ethyl alcohol/oil/Polysorbate 80 mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 2A.
Ingredient Quantity Estradiol 0.25 Ethyl Alcohol USP 8.8 gm Polysorbate 80 NF 9.4 m Soybean oil USP 50.2 gm Water USP 31.7 m The composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes. The particle size of the composition is detailed in Table 2B below and is further represented in Figure 5.
Table 2B
Mean ( m) Standard Deviation m 0.0826 0.048 Alternatively, estradiol can be dissolved in ethyl alcohol, the oil and water can be added to the estradiol solution, and water can be added to the resulting composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for minutes).
The particle size of the composition according to the Silverson method is detailed in Table 2C below and is further represented in Figure 6.
15 Table 2C
Mean (pm) Standard Deviation m 1.204 0.930 The resulting composition can be used directly as an estradiol topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 3 The piurpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention comprising the active agent testosterone.
Testosterone USP is a white to practically white crystalline powder chemically described as 17-beta hydroxyandrost-4-en-3-one.
H3.O H
OH
H H
Testosterone It has the chemical formula C19H2802 and a molecular weight of 288.42.
Testosterone is commercially available, for example, in a injectable dosage forms, transdermal gel (AndroGel , Testim8'), transdermal delivery device (Androdermo, Testoderm ), and a buccal drug delivery system (Striant ). Testosterone is used, for example, in hormone replacement therapy.
Testosterone was dissolved in ethyl alcohol. Oil and Polysorbate 80 were added to the testosterone solution, and water was added to the resulting composition.
The resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 3A.
Ingredient Quantity Testosterone 3.09 m Ethyl Alcohol USP 8.8 Polysorbate 80 NF 9.4 gm Soybean oil USP 50.2 gm Water USP 31.7 gm The testosterone/ethyl alcohol/oil/Polysorbate 80/water composition was fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure was tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes. The particle size of the composition is detailed in Table 3B below and is further represented in Figure 7.
Table 3B
Mean ( m) Standard Deviation (ttm) 1.052 0.507 Alternatively, the testosterone can be dissolved in ethyl alcohol, and oil and the Polysorbate 80 can be added to the testosterone solution. Water can be added to the testosterone/ethyl alcohol/oil/Polysorbate 80 composition under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a testosterone topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Examnle 4 The purpose of this example was to determine the effect of concentration of excipients on the antimicrobial properties of the formulation. The composition of Example I
was diluted with water by 10-fold and tested for antimicrobial effectiveness.
The quantities of each component are shown below in Table 4 Ingredient Quantity Ethyl Alcohol USP 0.88 gm Polysorbate 80-NF 0.94 gm Soybean oil USP 5.02 gm Water USP 93.16 This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards. The resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
Example 5 The purpose of this example was as yet another example to determine the effect of concentration of excipients on the antimicrobial properties of the formulation. The composition of Example 1 was diluted with water by 50-fold and tested for antimicrobial properties.
The quantities of each component are shown below in Table 4 Ingredient Quantity Eth 1 Alcohol USP 0.18 gm Polysorbate 80 NF 0.19 gm So bean oil USP 1.0 gm Water USP 98.63 gm This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards. The resulting composition cannot be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, nor can the composition be formulated into another suitable dosage form in order to impart antimicrobial properties.
Example 6 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, soybean oil, and Pluronic F-68 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer.
The quantities of each component are shown below in Table 6.
ln redient Quantity Eth l Alcohol USP 8.8 gm Pluronic F-68 6.0 gm So bean oil USP 50.2 gm Water USP 35.0 m The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 7 The purpose of this example was to describe preparation of an exemplary nanostructured composition according to the invention.
Ethyl alcohol, benzyl alcohol, isopropyl myristate, light mineral oil, and Pluronic F-68 were mixed together. Water was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 7.
Ingredient Quantity Ethyl Alcohol USP 10.6 Benzyl Alcohol 5.3 gm Pluronic F-68 7.4 gm Iso ro l Myristate 5.3 gm Light Mineral Oil 40.4 Water USP 30.9 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV- 1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
Alternatively, water can be added to the ethyl alcohol, oil, and Pluronic F-68 mixture under high-speed stirring using a rotor-stator assembly mounted on Silverson mixer (10,000 rpm for 15 minutes).
The resulting composition can be used directly as a topical lotion or cream having antibacterial, anti-viral, anti-fungal, and/or anti-yeast properties, or the composition can be formulated into another suitable dosage form.
Example 8 The purpose of this example was to describe preparation of a nanostructured composition that included propofol, a model active pharmaceutical ingredient, and that did not meet the USP Antimicrobial Effectiveness Testing standards.
Propofol, Ethyl alcohol, soybean oil, and Polysorbate 80 were mixed together.
Saline was then added to this mixture, and the resulting composition was mixed well using a paddle stirrer. The quantities of each component are shown below in Table 8.
Ingredient uanti Propofol 1.0 gm Ethyl Alcohol USP 0.5 gm Polysorbate 80 NF 0.9 Soybean oil USP 4.5 Saline 93.1 gm The composition was then fed into a high-pressure homogenizer (APV Invensys, model APV-1000) and the pressure tuned to 10,000 psi. The mixture was run through the homogenizer for 2 passes.
This formulation did not meet the criteria set forth when tested according to USP
Antimicrobial Effectiveness Testing standards.
Example 9 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 1.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as described in Example 1 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida Albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), Staphylococcus aureus (bacteria), Aspergillus fumigatus (fungus), and Aspergillus flavus (fungus).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of the organisms shown below in Table 4. The quantity of inoculum of the composition prepared as in Example 1 for each test is shown in Table 4, below. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation, at day 7, day 14, and at day 28. The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results of the tests are shown in Table 4. In addition, the results are graphically shown in Figure 1 and 2.
~'^~Qc~=~ o~ o A~ cn A~ tw~A~ on~
~--~ O q y o O~ O o O~ O O U
0~ Q~' N O^+V "Cl O"d TJ ~
00 U ~ Z V A V A Z O V I !~ Rdp.
L`t eA
.~ ..
C~ U U
(:N U .-O. d0 4, .~0. bA R.-O. OD a vi o -~ o A0 an =a A`~ oo r s A~ on C) N ^O,~ U y O c.a O r=O,~ U
O G O c~ d' "RC O ~ ~f' 'UR
V A VA ~.' Z V A
U bA a p d4 a~ b0 R
o~ o A`~ on~A~ ao aA~ ao Q O O ~
O O Oi~ ~td p~oet'7 O~ ~Y 'RU ?
N U N f-+ V A e7-+ V A I.N.
'cl ta U 0 2 OA a~ bD a~ bA a w o o ~ on'~A~ oo A~ oo=o ~
O r' '~! 'd O"' ~? C O
m 'U O
r"A
V A V d=
.~ p0 b ^CS 'LS ~
kn -~f=i CS U O ~ ~~ p a~i ~~ p~'~. 0 N
A~lo o A Uo+ o~
v-d ob o vv =~ ~ ~ ~ ~ z v n v n v n eG O ~ Cp v +- Ur E-1 3õ" ~ bA R O CU a~ bA a et ~Zi '~o U
o o A~ on'~A~ an A~ oq.o 0 U o~ o a~ " o o c~ o y o c W ~F=+ o~ o cso-- ~ o~ ~ ao~ o ~
ao , r.~ as c a ,_.; o--~ er zs --+ d b o- v v peLC~ '~ cv v w V V A 2 E" ..r ba v ~ ~U
o O
b q a~oi bA a a aD a E-+
~V o o en a U O~ O N v U y U.-~i v N V V =x=
E'~ O O a O.'"' R R O R
O d" "C O -" 'LS
v~i v rn Z V n P.' Z V h~ Z VA w y bA N d N
U c~ U
e.Hy+ ~ a'~ o A`r'o o~ A O o~ A O o~
O^'rY'C O^' d T! p N V Z V A Z V A Z V A
w Y K a bA
.~ U o ';"~+ a ~ a a "' U er o 0 ao ew cn o '.
0 C) o`~ o 0 0 0 0 0 ~ o 0 o na b o~
t~~' ~
~ C) .-~ .-~ ~-Ni N=-r .~. t~ c'~) I~i .~ ~
V
ci = N
O
H R, " o A A A
The results dramatically demonstrate the surprising effectiveness of the compositions of the invention as antibacterial, antifungal, and anti-yeast agents. For all but one tested organism (A. niger), all organisms were eradicated after 7 days, and for A.
niger, the growth of the organism was drastically diminished, with only 70 cfu/g measured on Day 28.
Moreover, the results demonstrate that the composition meets the USP 25 requirements for Antimicrobial Effectiveness Test.
Example 10 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 2, to determine if the addition of an active agent such as estradiol affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention. This example also evaluates the effect on antimicrobial activity of varying the quantity of alcohol present in the compositions of the invention.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of the organisms shown below in Table 5. The quantity of inoculum of the composition prepared as described in Example 2 for each test is shown in Table 5, below. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation, at day 14 (Table 5) and day 28 Table 6). The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results of the tests are shown in Tables 5 and 6. In addition, the results are graphically shown in Figure 3.
TABLE 5: Antimicrobial Effectiveness Test for Estradiol-Comprising Composition Day 14 Results Or anism A. niger C. albicans E. coli P. aeruginosa S. aureus Strain #
Inoculum 200,000 cfu/mL 250,000 cfu/mL 550,000 cfu/mL 220,000 cfu/mL 580,000 cfu/mL
per mL
12roduct % EtOH
7.7% 30,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 lo reduction > 4 lo reduction 7.3% 17,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 efu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7.4% 17,000 cfu/g None Detected None Detected None Detected None Detected 1 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfulg > 4 lo reduction > 4 log reduction > 4 log reduction > 4 log reduction 7.0% 13,000 cfu/g None Detected None Detected None Detected None Detected I log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction TABLE 6: Antimicrobial Effectiveness Test for Estradiol-Comprising Composition Day 28 Results Organism A. niger C. albicans E. coli P. aeruginosa S. aureus Strain #
Inoculum 200,000 cfu/mL 250,000 cfu/mL 550,000 cfu/mL 220,000 cfu/mL 580,000 cfu/mL
per mL
product % EtOH
7,7"/u None Detected None Detected None Detected None Detected None Detected <100 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g >3 log reduction > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7,3% None Detected None Detected None Detected None Detected None Detected <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction > 4 log reduction 7,4% 180 cfu/g None Detected None Detected None Detected None Detected 3.2 log reduction <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g > 4 lo reduction > 4 log reduction > 4 log reduction > 4 lo reduction 7,0% 100,000 cfu/g None Detected 180 cfu/g None Detected None Detected 0.5 log reduction <10 cfu/g 3.6 log reduction <10 cfu/g <l 0 cfu/g > 4 log reduction > 4 log reduction > 4 log reduction Example 11 The purpose of this example was to determine the antimicrobial effects of a composition prepared as described in Example 3, to determine if the addition of an active agent such as testosterone affects the antimicrobial, anti-yeast, anti-fungal, and/or anti-viral properties of the compositions of the invention.
Antimicrobial testing was conducted according to USP 25, <51>, pp. 1869-1871.
A
quantity of the composition prepared as in Example 2 was challenged with various bacteria, yeast, or fungus: Aspergillus niger (fungus), Candida albicans (yeast), Escherichia colf (bacteria), Pseudomonas aeruginosa (bacteria), and Staphylococcus aureus (bacteria).
Prior to the test, the surface of a suitable volume of solid agar medium was inoculated from a recently revived stock culture of each of A. niger, C. albicans, E.
coli, P. aeruginosa, and S. aureus. The quantity of bacteria, fungus, or yeast was measured at the time of inoculation and at day 7, 14, and 28. The culture conditions were conducted according to USP 25, <51>, pp. 1869-1871. The results, shown in Figure 4, dramatically demonstrate the surprising effectiveness of the compositions of the invention as antibacterial, anti-fungal, and anti-yeast agents when the compositions are used as drug delivery vehicles.
Surprisingly, the presence of an active agent does not negate the antimicrobial effects of the compositions of the invention. Moreover, the results demonstrate that the composition meets the USP 25 requirements for Antimicrobial Effectiveness Test.
It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
Claims (19)
1. An antimicrobial composition comprising an emulsion of:
(a) at least one solvent;
(b) at least one surfactant;
(c) at least one oil; and (d) water;
wherein the composition meets the United States Pharmacopeia (USP) testing requirements for antimicrobial effectiveness.
(a) at least one solvent;
(b) at least one surfactant;
(c) at least one oil; and (d) water;
wherein the composition meets the United States Pharmacopeia (USP) testing requirements for antimicrobial effectiveness.
2. The composition of claim 1, having antimicrobial effectiveness against one or more of E. coli (ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), C.
albicans (ATCC 10231), and A. niger (ATCC 16404).
albicans (ATCC 10231), and A. niger (ATCC 16404).
3. The composition of claim 2 having antimicrobial effectiveness against one or more of P. aeruginosa ATCC 13388), P. aeruginosa (ATCC 25619) A. flavus, and A.
fumigatus.
fumigatus.
4. The composition of claim 1, comprising a ratio of oil:stabilizer:solvent of about 23:
about 5: about 4, respectively, on a weight-to-weight basis.
about 5: about 4, respectively, on a weight-to-weight basis.
5. The composition of claim 1, comprising a ratio of the oil comprising phase to water or buffer of about 2: to about 1, respectively.
6. The composition of claim 1, comprising:
(a) the oil in about 10% to about 30% (w/w);
(b) the solvent in about 0.5% to about 10% (w/w);
(c) the surfactant in about 1% to about 8% (w/w);
(d) the water in about 20% to about 80 %(w/w); or (e) any combination thereof.
(a) the oil in about 10% to about 30% (w/w);
(b) the solvent in about 0.5% to about 10% (w/w);
(c) the surfactant in about 1% to about 8% (w/w);
(d) the water in about 20% to about 80 %(w/w); or (e) any combination thereof.
7. The composition of claim 1, further comprising: (a) at least one active agent dissolved in the solvent; (b) at least one active agent dissolved in the oil;
(c) at least one active agent dissolved in the water; (d) particles of at least one active agent present in the solvent; (e) particles of at least one active agent present in the oil; (f) particles of at least one active agent present in the water; (g) or a combination thereof.
(c) at least one active agent dissolved in the water; (d) particles of at least one active agent present in the solvent; (e) particles of at least one active agent present in the oil; (f) particles of at least one active agent present in the water; (g) or a combination thereof.
8. The composition of claim 7, wherein the active agent is acyclovir, cyclosporine, naltrexone, alendronic acid, ceterizine, nicotine, testosterone, progesterone, or estradiol.
9. The composition of claim 7, wherein the composition comprises globules of oil comprising dissolved active agent.
10. The composition of claim 9, wherein the oil globules have a particle size selected from the group consisting of less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, and less than about 100 nm in diameter.
11. The composition of claim 7, wherein the active agent particles, oil droplets comprising solubilized active agent, water droplets comprising solubilized agent, or a combination thereof, have a mean particle size of less than about 10 microns in diameter.
12. The composition of claim 11, wherein the active agent particles, oil droplets comprising solubilized active agent, water droplets comprising solubilized agent, or a combination thereof, have a mean particle size selected from the group consisting of less than about 9 microns, less than about 8 microns, less than about 7 microns, less than about 6 microns, less than about 5 microns, less than about 4 microns, and about 3 microns or greater in diameter.
13. The composition of claim 7, wherein the active agent particles, oil droplets comprising solubilized active agent, water droplets comprising solubilized agent, or a combination thereof, have a mean particle size of less than about 3 microns in diameter.
14. The composition of claim 13, wherein the active agent particles, oil droplets comprising solubilized active agent, water droplets comprising solubilized agent, or a combination thereof, have a mean particle size selected from the group consisting of less than about 2900 nm, less than about 2800 nm, less than about 2700 nm, less than about 2600 nm, less than about 2500 nm, less than about 2400 nm, less than about 2300 nm, less than about 2200 nm, less than about 2100 nm, less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, less than about 90 nm, less than about 80 nm, less than about 70 nm, less than about 60 nm, less than about 50 nm, less than about 40 nm, less than about 30 nm, less than about 20 nm, and less than about 10 nm.
15. The composition of claim 1, wherein the solvent is selected from the group consisting of isopropyl myristate, triacetin, N-methyl pyrrolidinone, aliphatic and aromatic alcohols, ethanol dimethyl sulfoxide, dimethyl acetamide, ethoxydiglycol, polyethylene glycols, and propylene glycol.
16. The method of claim 1, wherein the oil is oil is selected from the group consisting of almond oil (sweet), apricot seed oil, borage oil, canola oil, coconut oil, corn oil, cotton seed oil, fish oil, jojoba bean oil, lard oil, linseed oil (boiled), Macadamia nut oil, medium chain triglycerides, mineral oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, sunflower seed oil, tricaprylin (1,2,3-trioctanoyl glycerol), and wheat germ oil.
17. The method of claim 1, wherein the surfactant is selected from the group consisting of sorbitan esters, glycerol esters, polyethylene glycol esters, block polymers, acrylic polymers (such as Pemulen), ethoxylated fatty esters (such as Cremophor RH-40), ethoxylated alcohols (such as Brij), ethoxylated fatty acids (such as Tween 20), monoglycerides, silicon based surfactants, and polysorbates.
18. The method of claim 17, wherein the sorbitan ester surfactant is Span and Arlacel, wherein the glycerol ester is glycerin monostearate, wherein the polyethylene glycol ester is polyethylene glycol stearate, wherein the block polymer is a Pluronic, wherein the acrylic polymer is Pemulen, wherein the ethoxylated fatty ester is Cremophor RH-40, wherein the ethoxylated alcohol is Brij, and wherein the ethoxylated fatty acid is Tween 20.
19. A method of disinfecting a biological or non-biological surface comprising exposing the surface to a composition comprising:
(a) at least one solvent;
(b) at least one surfactant;
(c) at least one oil; and (d) water;
wherein the composition meets the United States Pharmacopeia (USP) testing requirements for antimicrobial effectiveness.
(a) at least one solvent;
(b) at least one surfactant;
(c) at least one oil; and (d) water;
wherein the composition meets the United States Pharmacopeia (USP) testing requirements for antimicrobial effectiveness.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78991706P | 2006-04-07 | 2006-04-07 | |
US60/789,917 | 2006-04-07 | ||
PCT/US2007/008054 WO2007123790A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2648360A1 true CA2648360A1 (en) | 2007-11-01 |
Family
ID=38436994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002648360A Abandoned CA2648360A1 (en) | 2006-04-07 | 2007-04-03 | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2010149A1 (en) |
JP (1) | JP2009533341A (en) |
CN (1) | CN101466355A (en) |
AU (1) | AU2007240983A1 (en) |
CA (1) | CA2648360A1 (en) |
WO (1) | WO2007123790A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
US20080139513A1 (en) * | 2006-09-26 | 2008-06-12 | Novavax, Inc. | Transdermal deliver of active agents |
US8932624B2 (en) | 2007-06-20 | 2015-01-13 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US9511040B2 (en) | 2007-06-20 | 2016-12-06 | The Trustees Of Columbia University In The City Of New York | Skin and surface disinfectant compositions containing botanicals |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US9687429B2 (en) | 2007-06-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Antimicrobial compositions containing low concentrations of botanicals |
CA2711807A1 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
MX2012000105A (en) * | 2009-06-30 | 2012-03-14 | Univ Columbia | Antimicrobial/preservative compositions comprising botanicals. |
ES2762405T3 (en) | 2011-11-03 | 2020-05-25 | Univ Columbia | Composition with sustained antimicrobial activity |
US9968101B2 (en) | 2011-11-03 | 2018-05-15 | The Trustees Of Columbia University In The City Of New York | Botanical antimicrobial compositions |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
WO2013086094A1 (en) | 2011-12-06 | 2013-06-13 | The Trustees Of Columbia University In The City Of New York | Broad spectrum natural preservative composition |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
FR2997304B1 (en) * | 2012-10-26 | 2017-07-07 | Isp Investments Inc | USE OF FLAX EXTRACT AS AN ACTIVATOR ACTIVE AGENT OF THE SYNTHESIS OF ANTIMICROBIAL PEPTIDES |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2947984A1 (en) * | 2013-01-25 | 2015-12-02 | Kemira Oyj | Biocide composition and method for treating water |
JP2017516768A (en) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Natural combination hormone replacement therapy and therapy |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
WO2017002117A1 (en) * | 2015-07-01 | 2017-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Delivery systems for propofol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN105241793B (en) * | 2015-09-07 | 2016-10-26 | 国家纳米科学中心 | A kind of assay method of carrier micelle form particle diameter |
CN106551902B (en) | 2015-09-17 | 2020-07-03 | 阿赖耶识(上海)生物技术有限公司 | High-stability non-vesicular nanoparticles and application thereof in treating microbial infection |
WO2017057743A1 (en) * | 2015-09-30 | 2017-04-06 | 富士フイルム株式会社 | Transdermally absorbable composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
KR20180126582A (en) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Steroid hormone pharmaceutical composition |
CN113728865B (en) * | 2021-09-24 | 2022-12-13 | 广西壮族自治区亚热带作物研究所(广西亚热带农产品加工研究所) | Comprehensive management method for promoting flower and protecting fruit of macadimia nuts |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629021A (en) * | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US6635676B2 (en) * | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
EP1633322A2 (en) * | 2003-06-04 | 2006-03-15 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
-
2007
- 2007-04-03 CA CA002648360A patent/CA2648360A1/en not_active Abandoned
- 2007-04-03 EP EP07754559A patent/EP2010149A1/en not_active Withdrawn
- 2007-04-03 WO PCT/US2007/008054 patent/WO2007123790A1/en active Application Filing
- 2007-04-03 CN CNA2007800213152A patent/CN101466355A/en active Pending
- 2007-04-03 AU AU2007240983A patent/AU2007240983A1/en not_active Abandoned
- 2007-04-03 JP JP2009504226A patent/JP2009533341A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2007240983A1 (en) | 2007-11-01 |
WO2007123790A1 (en) | 2007-11-01 |
EP2010149A1 (en) | 2009-01-07 |
CN101466355A (en) | 2009-06-24 |
JP2009533341A (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2648360A1 (en) | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties | |
Bajerski et al. | The use of Brazilian vegetable oils in nanoemulsions: an update on preparation and biological applications | |
US6635676B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
US6559189B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
Garcia et al. | Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils | |
São Pedro et al. | The use of nanotechnology as an approach for essential oil-based formulations with antimicrobial activity | |
US20070264349A1 (en) | Nano-structured compositions and methods of making and using the same | |
Pavoni et al. | Microemulsions: An effective encapsulation tool to enhance the antimicrobial activity of selected EOs | |
US8232320B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
US20100226983A1 (en) | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | |
US20110070306A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
AU2002350587A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
CN106727324B (en) | Nano silver liposome and its preparation method and application | |
CN101516358A (en) | Antiviral compositions and use thereof | |
Gondim et al. | Plant extracts loaded in nanostructured drug delivery systems for treating parasitic and antimicrobial diseases | |
CN101484138A (en) | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same | |
EP2633862B1 (en) | Compositions based on propolis nanocapsules which can be used as carriers for substances of interest, methods for producing same and use thereof | |
Manzoor et al. | Nanosizing of Lavender, Basil, and Clove Essential Oils into Microemulsions for Enhanced Antioxidant Potential and Antibacterial and Antibiofilm Activities | |
Elmowafy et al. | Delivery Systems of Plant-Derived Antimicrobials | |
WO2005030172A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
US11364199B1 (en) | Essential oil nanoemulsion and methods of use thereof | |
WO2023250135A1 (en) | Nanoemulsion composite mixture of essential oils, biodegradable polymers and co-surfactants for antimicrobial activities | |
Rai et al. | Formulation And Evaluation of microemulsion based Allicin for the treatment of Staph Infection | |
Kaur et al. | Nanoemulsions: Status in Antimicrobial Therapy | |
Cristiano et al. | 7 Technological Aspects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |